



Curriculum vitae Europass

Amplasare
FOTO

Informații personale	
Nume / Prenume	TOMULEASA CIPRIAN
E-mail(uri)	ciprian.tomuleasa@umfcluj.ro
Naționalitate(-tăți)	Romana
Data nașterii	24/07/1986
Locul nașterii (loc, județ)	Piatra Neamț, Jud. Neamț, Romania
Stare civilă	Căsătorit
Experiența profesională <i>(în ordine invers cronologică)</i>	
Perioada	2023-prezent
Funcția sau postul ocupat	Cercetător Științific I
Activități și responsabilități principale	Coordonarea echipei de Medicina Translațională a departamentului de Medicina Personalizata si Boli Rare
Numele și adresa angajatorului	Universitatea de Medicina si Farmacie „Iuliu Hatieganu” Cluj-Napoca, Romania – Institutul de Cercetare Biomedicala – Medfuture
Tipul activității sau sectorul de activitate	Cercetare/ Educație
Perioada	2025- prezent
Funcția sau postul ocupat	Conferențiar Universitare
Activități și responsabilități principale	Activitati de educatie – curs si lucrari practice nivel licenta, linia Romana si Engleza.
Numele și adresa angajatorului	Universitatea de Medicina si Farmacie „Iuliu Hatieganu” Cluj-Napoca, Romania – Departamentul de Hematologie
Tipul activității sau sectorul de activitate	Educație
Perioada	2017 – prezent
Funcția sau postul ocupat	Secretar general in comitetul de hematologie
Activități și responsabilități principale	-
Numele și adresa angajatorului	Ministerul Sanatatii Romania
Tipul activității sau sectorul de activitate	-
Perioada	2017 – prezent
Funcția sau postul ocupat	Secretar general in comitetul de terapii celulare
Activități și responsabilități principale	-

Numele și adresa angajatorului	Ministerul Sanatatii
Tipul activității sau sectorul de activitate	
Perioada	2017-2022
Funcția sau postul ocupat	Medic Specialist Hematolog
Activități și responsabilități principale	-
Numele și adresa angajatorului	Institutul Oncologic, Ion Chiricuta, Cluj-Napoca, Romania
Tipul activității sau sectorul de activitate	
Perioada	2017-2025
Funcția sau postul ocupat	Sef Lucrari
Activități și responsabilități principale	Activitati de educatie – curs si lucrari practice nivel licenta, linia Romana si Engleza.
Numele și adresa angajatorului	Universitatea de Medicina si Farmacie „Iuliu Hatieganu” Cluj-Napoca, Romania – Departamentul de Hematologie
Tipul activității sau sectorul de activitate	Educatie
Perioada	2020-2023
Funcția sau postul ocupat	Cercetator Stiintific II
Activități și responsabilități principale	-
Numele și adresa angajatorului	Universitatea de Medicina si Farmacie „Iuliu Hatieganu” Cluj-Napoca, Romania – Institutul de Cercetare Biomedicala – Medfuture
Tipul activității sau sectorul de activitate	-
Perioada	2015-2020
Funcția sau postul ocupat	Cercetator Stiintific III
Activități și responsabilități principale	-
Numele și adresa angajatorului	Universitatea de Medicina si Farmacie „Iuliu Hatieganu” Cluj-Napoca, Romania – Centrul de Cercetari Pentru Genomica Functionala.
Tipul activității sau sectorul de activitate	-
Perioada	2013-2016
Funcția sau postul ocupat	Medic Rezident Hematolog
Activități și responsabilități principale	-
Numele și adresa angajatorului	Universitatea de Medicina si Farmacie „Iuliu Hatieganu” Cluj-Napoca, Romania – Departamentul de Hematologie
Tipul activității sau sectorul de activitate	
Perioada	2013-2015
Funcția sau postul ocupat	Cercetator / Medic Cercetator
Activități și responsabilități principale	-
Numele și adresa angajatorului	Universitatea de Medicina si Farmacie „Iuliu Hatieganu” Cluj-Napoca, Romania – Centrul de Cercetari Pentru Genomica Functionala.

Tipul activității sau sectorul de activitate	
Perioada	2011-2013
Funcția sau postul ocupat	Postdoctorand
Activități și responsabilități principale	-
Numele și adresa angajatorului	Universitatea de Medicina „Johns Hopkins”, Baltimore, MD, SUA, departamentul de Medicina Interna, divizia de Gastroenterologie si hepatologie
Tipul activității sau sectorul de activitate	-
Perioada	2009-2011
Funcția sau postul ocupat	Asistent Universitare
Activități și responsabilități principale	-
Numele și adresa angajatorului	Universitatea de Medicina si Farmacie „Iuliu Hatieganu” Cluj-Napoca, Romania – Departamentul de Histologie
Tipul activității sau sectorul de activitate	
Perioada	2007-2011
Funcția sau postul ocupat	Asistent Cercetare
Activități și responsabilități principale	-
Numele și adresa angajatorului	Institutul Oncologic Ion Chiricuta, Cluj-Napoca, Romania, Departamentul de Imunologie
Tipul activității sau sectorul de activitate	
Educație și formare	<i>în ordine invers cronologică, se vor trece și cele mai importante studii post-universitare, post-doctorale, Burse studii, Stagii lucru</i>
Perioada	Septembrie 2018
Calificarea / diploma obținută	Visiting physicial
Disciplinele principale studiate / competențe profesionale dobândite	Training in imunoterapii in malignitati hematologice
Numele și tipul instituției de învățământ / furnizorului de formare	Departamentul de imunoterapii al Centrului National pentru cancer, Tokyo, Japonia – supervisor Prof. Shigehisa Kitano
Perioada	Septembrie 2017
Calificarea / diploma obținută	Visiting physician
Disciplinele principale studiate / competențe profesionale dobândite	Training in managementul clinic al complicatiilor aparute in transplantul allogenic de celule stem
Numele și tipul instituției de învățământ / furnizorului de formare	Departamentul de Celule stem al Centrului National pentru cancer, Tokyo, Japonia – supervisor Prof. Yoshihiro Inamoto
Perioada	Noiembrie 2017
Calificarea / diploma obținută	Visiting physician
Disciplinele principale studiate / competențe profesionale dobândite	Training in transplantul alogeneic de celule stem pentru celule T in malignitati

Numele și tipul instituției de învățământ / furnizorului de formare	Departamentul de imunoterapii al centrului Internațional pentru Cancer, Osaka, Japonia – supervisor Prof. Shigeo Fuji
Perioada	2016-2017
Calificarea / diploma obținută	EHA Fellow
Disciplinele principale studiate / competențe profesionale dobândite	Training pentru cercetare clinică și studii clinice
Numele și tipul instituției de învățământ / furnizorului de formare	Asociația Europeană de Hematologie (EHA)
Perioada	Iunie-Octombrie 2015
Calificarea / diploma obținută	Visiting Physician
Disciplinele principale studiate / competențe profesionale dobândite	Training în transplantul de celule stem haploidentice
Numele și tipul instituției de învățământ / furnizorului de formare	Universitatea din Texas, Centrul pentru Cancer MD Anderson, Texas, SUA, Departamentul de transplant celule stem și terapii celulare – coordonator Prof. Stefan Ciurea
Perioada	Iunie-Octombrie 2014
Calificarea / diploma obținută	Visiting Physician
Disciplinele principale studiate / competențe profesionale dobândite	Training în transplant de celule stem allogeneice
Numele și tipul instituției de învățământ / furnizorului de formare	Universitatea din Texas, Centrul pentru Cancer MD Anderson, Texas, SUA, Departamentul de transplant celule stem și terapii celulare – coordonator Prof. Stefan Ciurea
Perioada	2013-2016
Calificarea / diploma obținută	Medic Rezident
Disciplinele principale studiate / competențe profesionale dobândite	Rezidentiat în Hematologie
Numele și tipul instituției de învățământ / furnizorului de formare	Institutul Oncologic „Ion Chiricuta” Cluj-Napoca, România, Departamentul de Hematologie – supervisor Dr. Delia Dima și Prof. Andrei Cucuianu
Perioada	2011-2013
Calificarea / diploma obținută	Student Doctorand
Disciplinele principale studiate / competențe profesionale dobândite	Doctorat în imunologia cancerului
Numele și tipul instituției de învățământ / furnizorului de formare	Universitatea de Medicină și Farmacie „Iuliu Hatieganu” Cluj-Napoca, România – Departamentul de Imunologie – coordonator Prof. Vasile Cristea
Perioada	2011-2013
Calificarea / diploma obținută	Postdoctorand
Disciplinele principale studiate / competențe profesionale dobândite	Studiul biologiei celulelor tumorale
Numele și tipul instituției de învățământ / furnizorului de formare	Universitatea de Medicină „Johns Hopkins”, Baltimore, MD, SUA, departamentul de Medicină Internă, divizia de Gastroenterologie și hepatologie – Coordonator Prof. Florin Selaru
Perioada	2005-2011
Calificarea / diploma obținută	Student – Medicină generală

Disciplinele principale studiate / competențe profesionale dobândite	Medicina
Numele și tipul instituției de învățământ / furnizorului de formare	Universitatea de Medicina si Farmacie „Iuliu Hatieganu” Cluj-Napoca, Facultatea de Medicina
Membru al unei Academii din România	Se vor preciza: numele Academiei, calitatea de membru și anul din care este membru
Membru al unei Academii din străinătate	Se vor preciza: numele Academiei, țara, orașul, calitatea de membru și anul din care este membru
Membru al unor organizații științifice sau profesionale	Se vor preciza: numele organizației științifice, țara, orașul, calitatea de membru și anul din care este membru 1. 2014-prezent – membru al Asociației Europene de Hematologie (EHA) 2. 2014-prezent – membru al Societății Americane de Hematologie (ASH) 3. 2017-prezent – membru al Societății Romane de Hematologie (SRH) 4. 2008- prezent – membru al Societatii romane de Radioterapie si Oncologie Medicinala 5. 2016-prezent – membru fondator al Societatii Romane de Transplant Medular (SRBMT) 6. 2019-prezent – membru al Societatii Japoneze de Hematologie 7. 2025-prezent – membru al Societatii Britanice de Hematologie
Membru în Comitetul științific de organizare a unei manifestări științifice	Se vor preciza: perioada, tipul manifestării, instituții organizatoare, unde a avut loc [țara, oraș] – eventual dacă a fost și conducătorul manifestării [principalul organizator] 1. 11.09.2015 - Presedinte congres: Nanotechnology in leukemia chemotherapy 2. 11-12 Martie 2016 – Presedinte congres – Editia 1 Insights in Hematology 3. 10-11 Martie 2017 – Presedinte congres – Editia 2 Insights in Hematology 4. 09.09.2017 – Hematology Summit Forum – Beijing China 5. 9-10 Martie 2018 – Presedinte congres – Editia 3 Insights in Hematology 6. 19-20 Septembrie 2019 – Presedinte congres – Editia 4 Insights in Hematology 7. 19-20 Septembrie 2020 – Presedinte congres – Editia 5 Insights in Hematology 8. 19-20 Septembrie 2021 – Presedinte congres – Editia 6 Insights in Hematology 9. 19-20 Septembrie 2022 – Presedinte congres – Editia 7 Insights in Hematology 10. 10-12 Septembrie 2023 – Presedinte congres – Editia 8 Insights in Hematology 11. 9-10 Mai 2024 – Presedinte congres – Editia 9 Insights in Hematology

Membru in Colegiul de redacție / referent al unei reviste	<p>Se vor preciza: titlul revistei, editura, ISSN, factor de impact al revistei, frecvența de apariție – eventual dacă conduceți chiar dvs. revista</p> <ol style="list-style-type: none"> 1. 2018 – prezent – membru editorial al Medicine and Pharmacy Reports 2. 2018 – prezent – membru editorial al Journal of Clinical Medicine 3. 2019 – prezent – membru editorial al Annals of Translational Medicine 4. 2019 – editor invitat Frontiers in Pharmacology 5. 2020 – editor invitat Frontiers in Medicine 6. 2021 – editor invitat Frontiers in Medicine 7. 2025 – editor invitat Frontiers in Medicine 									
PREMII INTERNATIONALE	<p>Se vor preciza: titlul premiului, instituția care vi l-a acordat și anul premierii</p> <ol style="list-style-type: none"> 1. 2. <p>.....</p>									
PREMII NATIONALE	<p>Se vor preciza: titlul premiului, instituția care vi l-a acordat și anul premierii</p> <ol style="list-style-type: none"> 1. 2. <p>.....</p>									
Aptitudini și competențe personale										
Limba(i) maternă(e)	Română									
Limba(i) străină(e) cunoscută(e)										
Autoevaluare	Înțelegere				Vorbire				Scriere	
<i>Nivel european (*)</i>	Ascultare		Citire		Participare la conversație		Discurs oral		Exprimare scrisă	
Limba engleză	C2		C2		C2		C2		C2	
Limba franceză										
Limba rusă										
Limba italiană										
(*) Nivelul Cadrului European Comun de Referință Pentru Limbi Străine										
Competențe și abilități sociale	Adaptabilitate, Mentorat, Coaching, Public speaking, Networking, Aptitudini clinice și de relaționare cu pacienții									
Competențe și aptitudini organizatorice	Management de proiecte, Managementul timpului, Eficiență în rezolvarea problemelor, Leader de grup									
Competențe și aptitudini de utilizare a calculatorului	Operare MS Office. Word, Excel, Outlook, Powerpoint, GraphPad Google Drive. Docs, Drive, Forms, Gmail, Sheets. Gestionarea site-urilor web									
Competențe și aptitudini artistice	Abilități de scriere și exprimare liberă pe teme multiple, creativitate în idei, pasiune pentru cultura și istoria universală									
Alte competențe și aptitudini	Viziune și agilitate a minții, Perseverență și determinare, optimism									
Relațional	Leadership, Comunicarea eficientă, Empatia, Negocierea									
Permis(e) de conducere	Da, tip B									

Informații suplimentare	
Anexe (v. Anexa 4 de la pagina 9, de mai jos)	LISTA DE LUCRĂRI ȘTIINȚIFICE Membru / Expert / Responsabil / Director - ÎN ECHIPA DE CERCETARE în cadrul unor proiecte de cercetare

ANEXA 4. LISTA LUCRARI STIINTIFICE

Carti:

1. NANOPHARMACOLOGY IN LEUKEMIA CHEMOTHERAPY. Andrei Cucuianu, **Ciprian Tomuleasa**, Anca Bojan, Cristian Berce, Simion Astilean, Emmet McCormack. Editura Cartea Ardeleana, Cluj Napoca, 2015. ISBN 978-606-8699-74-5.
2. CHIMIOTERAPIE HEMATOLOGICA. **Ciprian Tomuleasa**, Mariana Patiu, Anca Bojan, Mihnea Zdrenghea, Cristian Berce, Ioana Frinc, Bobe Petrushev, Delia Dima, George Calin, Alina Tanase, Stefan Ciurea. Editura Cartea Ardeleana, Cluj Napoca, 2016. ISBN 978-606-8770-30-7.
3. HEMATOLOGIA IN IMAGINI. Delia Dima, Mariana Patiu, Anca Bojan, **Ciprian Tomuleasa**. Editura Cartea Ardeleana, Cluj Napoca, 2016. ISBN 978-606-8770-69-7.
4. LEUCEMIA MIELOIDA CRONICA. DE LA TERAPIA CU INHIBITORI DE TIROZIN KINAZE LA TRANSPLANT. **Ciprian Tomuleasa**, Delia Dima, Adrian Trifa. Editura Cartea Ardeleana, Cluj Napoca, 2016. ISBN 978-606-8770-98-7.
5. NEOPLASMELE MIELOPROLIFERATIVE. Cristina Bagacean, Iulia Berceanu, Delia Dima, Bogdan Fetica, Jean-Cristophe Ianotto, Mariana Patiu, Adrian Tempescul, **Ciprian Tomuleasa**, Adrian Trifa, Mihnea Zdrenghea. Sub redactia Mihnea Zdrenghea. Editura Casa Cartii de Stiinta, Cluj Napoca, 2017. ISBN 978-606-17-1135-2.
6. GHID DE TRANSPLANT MEDULAR. Alina Tanase, **Ciprian Tomuleasa**. Editura Cartea Ardeleana, ISBN 978-606-797-156-9, Cluj Napoca, 2017.
7. GHIDUL ADULTULUI CU HEMOFILIE. Melen Brinza, Cristina Tarniceriu, Adina Traila, **Ciprian Tomuleasa**. Editura Medicala. ISBN 978-973-39-0941-5, Bucuresti, 2023

Capitole de carti:

Edituri Internationale:

1. TYPES OF RESEARCH DESIGNS. Fedor Moissenko, Cornelia Braicu, **Ciprian Tomuleasa**, Ioana Berindan-Neagoie. In "CANCER RESEARCH AND CLINICAL TRIALS IN DEVELOPING COUNTRIES". Springer Science Books, ISBN 978-3-319-18443-2, Cape Town, South Africa 2016.

2. THEORETICAL MODELS OF HEMATOPOIETIC CELL DYNAMICS RELATED TO BONE MARROW TRANSPLANTATION. Radu Precup, Delia Dima, Ciprian Tomuleasa, Marcel Adrian Serban, Lorand Parajdi. In "Frontiers in Stem Cell and Regenerative Medicine Research". Betham Science Publishers, 2017.

3. NON-CODING RNAs IN LUNG CANCER ANGIOGENESIS. Cornelia Braicu, Ciprian Tomuleasa, Diana Gulei, George Adrian Calin, Ioana Berindan-Neagoe. In "[Physiologic and Pathologic Angiogenesis - Signaling Mechanisms and Targeted Therapy](#)", book edited by Dan Simionescu and Agneta Simionescu, ISBN 978-953-51-3024-6, Print ISBN 978-953-51-3023-9, 2017.

4. PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA. Mihnea Zdrenghea, Delia Dima, **Ciprian Tomuleasa**, Horia Bumbea, Cristina Bagacean. In " New Approaches to the Management of Primary and Secondary CNS Tumors is published " Intech, ISBN 978-953-51-3052-9, 2017.

5. THE USEFULNESS OF BIOMARKERS FOR DIAGNOSIS. Patric Teodorescu, Sergiu Pasca, **Ciprian Tomuleasa**. In "Pineal region lesions. Management strategies and controversial issues. Springer – Zurich, 2020, ISBN 978-3-030-50912-5.

Edituri nationale:

1. CORELATII CLINICO-GENETICO-MOLECULARE IN ONCO-HEMATOLOGIE. **Ciprian Tomuleasa**, Delia Dima. In "PROTOCOALE DE DIAGNOSTIC SI TRATAMENT IN HEMATOLOGIE". Andrei Cucuianu. Editura Casa Cartii de Stiinta, Cluj Napoca 2014.

2. ROLUL PROGNOSTIC AL CITOGENETICII SI AL BIOLOGIEI MOLECULARE IN TRANSPLANTUL AUTOLOG DE CELULE STEM HEMATOPOIETICE. **Ciprian Tomuleasa**, Delia Dima, Alina Tanase. In "AUTOTRANSPLANTUL DE CELULE STEM HEMATOPOIETICE IN HEMOPATIILE MALIGNNE". Alina Daniela Tanase, Carmen Orban. Editura Techno Media, Bucharest 2015.

3. REGIMURI DE CONDITIONARE. Alina Tanase, **Ciprian Tomuleasa**. In "AUTOTRANSPLANTUL DE CELULE STEM HEMATOPOIETICE IN HEMOPATIILE MALIGNNE". Alina Daniela Tanase, Carmen Orban. Editura Techno Media, Bucharest 2015.

4. EVALUAREA CARDIACA PENTRU TRANSPLANTUL DE CELULE STEM HEMATOPOIETICE. **Ciprian Tomuleasa**, Sergiu Pasca, Anca Bojan, Delia Dima. In "MANUAL DE CARDIOONCOLOGIE". Cristina Vlad, Dan Radulescu, Simona Dragan, Claudia Burz. Editura Medicala Universitara Iuliu Hatieganu 2020.

Lista articole ISI:

1. RECEPTOR TYROSINE KINASES IN CANCER. ONCOGENIC MOLECULAR ALTERATIONS TO THERAPEUTIC HORIZONS IN PRECISION MEDICINE. **Ciprian Tomuleasa**, Adrian-Bogdan Tigu, Raluca Munteanu, Cristian-Silviu Moldovan,

- David Kegeyes, Anca Onaciu, Diana Gulei, Gabriel Ghiaur, Hermann Einsele, Carlo M. Croce. Signal Transduction and Targeted Therapy 2024, **impact factor: 40.6**, in press.
2. HORIZON 2020. FUNDS TO HELP EASTERN EUROPE CLOSE THE GAP. Cristian Berce, **Ciprian Tomuleasa**, Radu Meza. Nature 2017, 541(7636):157-157. **impact factor: 38.138**.
 3. PATIENT SELECTION FOR CAR-T OR BITE THERAPY IN MULTIPLE MYELOMA. WHICH TREATMENT FOR EACH PATIENT? David Kegeyes, Catalin Constantinescu, Louise Vrancken, Leo Rasche, Celine Gregoire, Bogdan Tigu, Delia Dima, Diana Gulei, Alina Tanase, Hermann Einsele, Stefan Ciurea, **Ciprian Tomuleasa**, Jo Caers. Journal of Hematology and Oncology 2022, **impact factor: 23.168**, in press.
 4. INSIGHTS INTO THE ROLES OF UBIQUITIN LIGASE KPC1: FROM CELL CYCLE CONTROL TO NF-KB REGULATOR. Diana Gulei, Rares Drula, Gabriel Ghiaur, Anca Dana Buzoianu, **Ciprian Tomuleasa**, Aaron Ciechanover. Cancer Research, 2023, in press. **impact factor: 13.312**.
 5. CONTINUOUS RENAL REPLACEMENT THERAPY IN CYTOKINE RELEASE SYNDROME FOLLOWING IMMUNOTHERAPY OR CELLULAR THERAPIES? Catalin Constantinescu, Sergiu Pasca, Tiberiu Tat, Patric Teodorescu, Catalin Vlad, Sabina Iluta, Dana Tomescu, Delia Dima, Ecaterina Scarlatescu, Alina Tanase, Anca Colita, Olafur Eysteinn Sigurjonsson, Hermann Einsele, **Ciprian Tomuleasa**. Journal of Immunotherapy of Cancer, 2020, in press. **impact factor: 12.469**.
 6. DESIGN AND IMPLEMENTATION OF A HUMANITARIAN CANCER PROGRAM FOR UKRAINIAN REFUGEES IN MOLDOVA AND ROMANIA. Horia Vulpe, et al, **Ciprian Tomuleasa**, Gabriel Ricu, Rodica Mindruta-Stratan, Catalin Danaila, Dragos Iancu, Ludmila Circiumari, Cristian Teglas, Lars Lonnback, Violina Nazaria, Ursula Wagner, Eugenia Ciubotaru, Nicoleta Minzatean, Ciprian Jitaru, Sanislav Polozov, Inessa Matiushenko, Anna Uzlova, Richard Sullivan, Stefania Magidson. Lancet Oncology, 2023, in press. **impact factor: 51.1**.
 7. THE INTERPLAY BETWEEN CANCER CELLS, MACROPHAGES AND NATURAL KILLER CELLS MAY ACTUALLY DECIDE THE OUTCOME OF THERAPY WITH SORAFENIB. **Tomuleasa C**, Giannelli G, Cucuianu A, Aldea M, Paradiso A, Berindan-Neagoe I. [Hepatology](#). 2014; 60(1):430. **impact factor: 12.008**.
 8. HUMAN BILE CONTAIN MICRORNA-LADEN EXOSOMES THAT CAN BE USED FOR CHOLANGIOCARCINOMA DIAGNOSIS. Ling Li, David Masica, Masaharu Ishida, **Ciprian Tomuleasa**, Sho Umegaki, Anthony N. Kalloo, Christos Georgiades, Vikesh K. Singh, Mouen Khashab, Stuart Amateau, Zhiping Li, Patrick Okolo, Anne-Marie Lennon, Payal Saxena, Jean-Francois Geschwind, Todd Schlachter, Kelvin Hong, Timothy M. Pawlik, Marcia Canto, Joanna Law, Reem Sharaiha, Clifford R. Weiss, Haoran Peng, Paul Thuluvath, Michael Goggins, Eun Ji Shin, Vivek Kumbhari, Susan Hutfless, Liya Zhou, Esteban Mezey, Stephen J. Meltzer, Rachel Karchin, Florin M. Selaru. [Hepatology](#). 2014;60(3):896-907. **impact factor: 12.008**.
 9. CANCER-ASSOCIATED RS6983267 SNP AND ITS ACCOMPANYING RNA CCAT2 INDUCE MYELOID MALIGNANCIES VIA UNIQUE SNP-SPECIFIC RNA MUTATIONS. Maitri Shah, Valentina Pileczki, Linda Fabris, Manuela Ferracin, Roxana Redis, Maria Ciccone, Xinna Zhang, Masayoshi Shimizu, Cristian Rodriguez-Aguayo, Maria Angelica Cortez, Cristina Ivan, Taghi Manshouri, Steliana Calin, Jan Parker-Thornburg, Asha Multani, James Welsh, Marcos Estecio, Hui Ling, **Ciprian Tomuleasa**,

Delia Dima, Hui Yang, M. James You, Srdan Verstovsek, Milan Radovich, Katy Rezvani, Elizabeth Shpall, Leonard Girnita, Ioana Berindan-Neagoe, Riccardo Fodde, Carlos Bueso-Ramos, Mihai Gagea, Guillermo Garcia-Manero, Ines Almeida, Daniela Nedelcu, Muharrem Muftuoglu, Pinaki Banerjee, Mustafa Badiwi, George Calin. *Genome Research* 2017, **impact factor: 11.351.**

10. UNEXPLAINED HEMORRHAGIC SYNDROME? CONSIDER ACQUIRED HEMOPHILIA A OR B. Catalin Constantinescu, Ciprian Jitaru, Sergiu Pasca, Delia Dima, Noemi Dirzu, Daniel Coriu, Joanna Zdziarska, Gabriel Ghiaur, Johny Mahlangu, **Ciprian Tomuleasa**. *Blood Reviews*, 2021, in press. **impact factor: 10.626.**
11. EXPLOITING THE UBIQUITIN SYSTEM IN MYELOID MALIGNANCIES. FROM BASIC RESEARCH TO DRUG DISCOVERY IN MDS AND AML. Rares Drula, Sabina Iluta, Diana Gulei, Delia Dima, Cristina Iuga, Anca Dana Buzoianu, Gabriel Ghiaur, Aaron Ciechanover, **Ciprian Tomuleasa**. *Blood Reviews*, 2022, in press. **impact factor: 10.626.**
12. SWITCHING FROM SALVAGE CHEMOTHERAPY TO IMMUNOTHERAPY IN ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA. David Kegyes, Ciprian Jitaru, Gabriel Ghiaur, Stefan Ciurea, Dieter Hoelzer, **Ciprian Tomuleasa**, Robert Peter Gale. *Blood Reviews*, 2023, **impact factor: 10.626.** in press.
13. PROTEASOME INHIBITION IN COMBINATION WITH IMMUNOTHERAPIES: STATE-OF-THE-ART IN MULTIPLE MYELOMA. David Kegyes, Diana Gulei, Rares Drula, Diana Cenariu, Bogdan Tigiu, Delia Dima, Alina Tanase, Sorina Badelita, Anca-Dana Buzoianu, Stefan Ciurea, Gabriel Ghiaur, Evangelos Terpos, Aaron Ciechanover, Hermann Einsele, **Ciprian Tomuleasa**. *Blood Reviews*, 2023, in press, **impact factor: 10.636.**
14. DIVINE MESSENGERS: ARE EXOSOMES THE HERMESES OF MODERN MOLECULAR ONCOLOGY? **Ciprian Tomuleasa**, Cornelia Braicu, Pamela Monroig, Andrei Cucuianu, Ioana Berindan-Neagoe, George A. Calin. [Cell Death Differentiation](#). 2015; 22(1):34-45. **impact factor: 8.371.**
15. NANOMEDICINE FOR ACUTE LYMPHOBLASTIC LEUKEMIA DETECTION AND TREATMENT. Andra Sorina Tatar, Timea Simon, Simion Astilean, **Ciprian Tomuleasa**, Sanda Boca. *Journal of Controlled Release*, 2016; 238:123-38. **impact factor: 8.407.**
16. REAL WORLD TREATMENT PATTERNS AND HEALTHCARE RESOURCE USE IN PATIENTS WITH MYELOFIBROSIS: RESULTS FROM THE METER STUDY. Vikas Gupta, **Ciprian Tomuleasa**, Gilberto Israel Barranco Lampon, Hsin-An Hou, Grzegorz Helbig, Pankit Vachhani, Argiris Symeonidis, Ibrahim Haznedaroglu, Kenny Galvez, Fernando Tatsch, Avijeet S Chopra, Meng Zhang, Tamas Vizkelety, Bryan Murray, David M Ross. *Blood Advances* 2024, submitted for publication. **impact factor: 7.6.**
17. UNLOCKING PROTEIN-BASED BIOMARKER POTENTIAL FOR GRAFT VERSUS HOST DISEASE FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTS. Maria Iacobescu, Cristina Pop, Alina Uifălean, Cristina Ionela Mogoșan, Diana Cenariu, Mihnea Zdrengea, Alina Daniela Tănase, Jon Thor Bergthorsson, Victor Greiff, Mihai Cenariu, Cristina Adela Iuga, **Ciprian Tomuleasa**. Dan Tătaru. *Frontiers in Immunology* 2024, in press. **impact factor: 7.3.**

18. ANTIBODY CONJUGATED, RAMAN-TAGGED HOLLOW GOLD NANOSPHERES FOR SPECIFIC TARGETING AND MULTIMODAL DF/SERS/TPE-FLIM IMAGING OF CD19(+) B LYMPHOBLASTS. Timea Nagy-Simon, Andra-Sorina Tatar, Ana-Maria Craciun, Adriana Vulpoi, Maria-Ancuta Jurj, Adrian Florea, **Ciprian Tomuleasa**, Ioana Berindan-Neagoe, Simion Astilean, Sanda Boca. [ACS Applied Materials & Interfaces](#), in press. **impact factor: 7.145.**
19. THE ROLE OF MICRORNAS IN THE PATHOGENESIS OF HIV-RELATED LYMPHOMAS. Ravnit Grewal, Andrei Cucuianu, Carmen Swanepoel, Delia Dima, Bobe Petrushev, Bogdan Pop, Ioana Berindan-Neagoe, Emmanuel Akin Abayomi, **Ciprian Tomuleasa**. *Critical Reviews in Clinical Laboratory Sciences* 2015, 52(5):232-41. **impact factor: 7.00.**
20. NEURO-TOXICITIES OF CHEMO- AND IMMUNE-THERAPIES IN HAEMATOLOGICAL MALIGNANCIES : FROM MECHANISM TO MANAGEMENT. David Keyes, Vlad Moisoiu, Catalin Constantinescu, Alina Tanase, Gabriel Ghiaur, Hermann Einsele, **Ciprian Tomuleasa**, Hillard Lazarus, Robert Peter Gale. *Blood Reviews* 2024, in press. **impact factor: 6.9.**
21. PITFALLS IN PATENTING ACADEMIC CAR-T CELLS THERAPY. Catalin Constantinescu, Roxana Constantinescu, Jon Thor Bergthorsson, Victor Greiff, Alina Tanase, Anca Colita, Diana Gulei, **Ciprian Tomuleasa**. *Expert Opinion on Therapeutic Patents*, 2023, impact factor: 6.714, in press.
22. PSEUDOGENE INTS6P1 REGULATES IT'S CONGNATE GENE INTS6 THROUGH COMPETITIVE BINDING OF MIR-17-5P IN HEPATOCELLULAR CARCINOMA. Haoran Peng, Masaharu Ishida, Atsushi Saito, Atsushi Kamiya, James P. Hamilton, Rongdang Fu, Alexandru V. Olaru, Fangmei An, Irinel Popescu, Razvan Iacob, Simona Dima, Sorin T. Alexandrescu, Razvan Grigorie, Anca Nastase, Ioana Berindan-Neagoe, **Ciprian Tomuleasa**, Florin Graur, Florin Zaharia, Michael S. Torbenson, Esteban Mezey, Minqiang Lu, Florin M. Selaru. *Oncotarget* 2015; ;6(8):5666-77. **impact factor: 6.63.**
23. TRANSIENT LEUKEMIA OF DOWN SYNDROME. Sas Valentina, Blag Cristina, Zaharie Gabriela, Andronic-Gorcea Nicolae, Pasca Sergiu, Petrushev Bobe, Chis Irina, Marian Mirela, Dima Delia, Zdrenghea Mihnea, Berindan-Neagoe Ioana, Popa Gheorghe, Man Sorin, Colita Anca, Stefan Cristina, Kojima Seiji, **Tomuleasa Ciprian**. *Critical Reviews in Clinical Laboratory Sciences*, 2019, in press. **impact factor: 6.481.**
24. THE NF-KB P50 SUBUNIT GENERATED BY KPC1-MEDIATED UBIQUITINATION AND LIMITED PROTEASOMAL PROCESSING, SUPRESSES TUMOR GROWTH. Yelena Kravtsova-Ivantsiv, Gilad Goldhirsh, Ciprian Tomuleasa, Eli Pikarsky, Aaron Ciechanover. *Cancer Cell International* 2023, in press. impact factor: 6.436.
25. MICRORNAS ASSOCIATED WITH A GOOD PROGNOSIS OF ACUTE MYELOID LEUKEMIA AND THEIR EFFECT ON MACROPHAGE POLARIZATION. Alexandra Neaga, Cristina Bagacean, Adrian Tempescul, Laura Jimbu, Oana Mesaros, Cristina Lucia Blag, **Ciprian Tomuleasa**, Corina Bocsan, Mihaela Gaman, Mihnea Zdrenghea. *Frontiers in Immunology*, 2020, in press, **impact factor: 6.429.**
26. IMMUNE THERAPIES OF B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA IN CHILDREN AND ADULTS. David Keyes, Gabriel Ghiaur, Anamaria Bancos, **Ciprian**

- Tomuleasa, Robert Peter Gale. Critical Reviews in Oncology / Hematology, 2024, in press. impact factor: 6.2.**
27. A COMPREHENSIVE PICTURE OF EXTRACELLULAR VESICLES AND THEIR CONTENT. Ancuta Jurj, Oana Zanoaga, Cornelia Braicu, Vladimir Lazar, **Ciprian Tomuleasa**, Alexandru Irimie, Ioana Berindan-Neagoe. *Cancers*, 2020, in press. **impact factor: 6.102.**
 28. THERAPEUTIC ADVANTAGES IN THE TARGETING OF ROR1 IN HEMATOLOGICAL CANCERS. Adrian Bogdan Tigu, **Ciprian Tomuleasa**, Raluca Munteanu, Cristian Moldovan, Rareş Drula, Radu Tomai, David Kegyes, Vlad Moisoiu, Gabriel Ghiaur, Diana Gulei, Hermann Einsele, Carlo M. Croce. *Cell Death Discovery* 2024, **impact factor: 6.1**, in press.
 29. CHARACTERISTICS OF DENTAL RESIN BASED COMPOSITES IN LEUKEMIA SALIVA: AN IN VITRO ANALYSIS. Alexandru Mester, Marioara Moldovan, Stanca Cuc, **Ciprian Tomuleasa**, Sergiu Pasca, Miuta Filip, Andra Piciu, Florin Onisor. *Biomedicines* 2021, in press. **impact factor: 6.081.**
 30. MIR-543 REGULATES THE EPIGENETIC LANDSCAPE OF MYELOFIBROSIS BY TARGETTING TET1 AND TET2. Enrique Fuentes-Mattei , Recep Bayraktar, Taghi Manshour, Andreia Silva, Cristina Ivan, Diana Gulei, Linda Fabris, Nayra Soares, Pilar Mur, Cristina Perez-Caro, Elizabeth Torres-Claudio, Mihnea Dragomir, Adriana Grisselle Badillo, Erik Knutsen, Pranav Narayanan, Leonard Golfman, Masayoshi Shimizu, Xinna Zhang, Wanke Zhao, Wanting Ho, Marcos R. H. Estecio, Geoffrey Bartholomeusz, **Ciprian Tomuleasa**, Ioana Berindan-Neagoe, Patrick Zweidler-McKay, Zeev Estrov, Joe Zhao, Srdan Verstovsek, George A. Calin, Roxana Redis. *Journal of Clinical Investigation Insights*, 2020, in press, **impact factor: 6.014.**
 31. PATTERNS OF HEALTHCARE RESOURCE UTILIZATION (HRU) IN UNFIT PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) RECEIVING FIRST LINE SYSTEMIC TREATMENT OR BEST SUPPORTIVE CARE (BSC): A MULTICENTER INTERNATIONAL STUDY (CURRENT). T Ito, D Sanford, **C Tomuleasa**, HH Hsiao, LJ Enciso Oliveira, AK Enjeti, Conca A Gimenez, T Barnal del Castillo, L Girsova, MP Martelli, B Guvenc, CN Bui, A Delgado, Y Duan, B Garbavo Guijarro, C Llamas, JH Lee. *Value in Health*, 2021, in press, **impact factor: 6.**
 32. SERS-BASED EVALUATION OF METHYLATION PROGRESSION IN CLONAL LEUKEMOGENESIS OF DOWN SYNDROME. Vlad Moisoiu, Valentina Sas, Andrei Stefanu, Stefania D. Iancu, Ancuta Jurj, Sergiu Pasca, Sabina Iluta, Alina-Andreea Zimta, Adrian B. Tigu, Delia Dima, Patric Teodorescu, Cristina Turcas, Cristina Blag, Delia Dima, Gheorghe Popa, Smaranda Arghirescu, Sorin Man, Anca Colita, Nicolae Leopold, **Ciprian Tomuleasa**. *Frontiers in Bioengineering and Biotechnology*, 2021, in press, **impact factor: 5.89.**
 33. NOVEL INSIGHTS INTO TRIPLE-NEGATIVE BREAST CANCERS, THE EMERGING ROLE OF ANGIOGENESIS, AND ANTIANGIOGENIC THERAPY. Cornelia Braicu, Roxana Chiorean, Alexandru Irimie, Sergiu Chira, **Ciprian Tomuleasa**, Emilian Neagoe, Angelo Paradiso, Patriciu Achimas-Cadariu, Vladimir Lazar, Ioana Berindan-Neagoe. *Expert Reviews in Molecular Medicine*. 2016; 18:e18. **impact factor: 5.71.**
 34. CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA. **Ciprian Tomuleasa**, Shigeo Fuji, Cristian

- Berce, Anca Onaciu, Sergiu Chira, Bobe Petrushev, Wilhelm Thomas Micu, Vlad Moisoiu, Sergiu Pasca, Ciprian Osan, Catalin Constantinescu, Ancuta Jurj, Laura Pop, Ioana Berindan-Neagoe, Delia Dima, Shigehisa Kitano. *Frontiers in Immunology*, in press. **impact factor: 6.429.**
35. THE POTENTIAL EQUIVALENTS OF TET2 MUTATIONS. Sergiu Pasca, Ancuta Jurj, Mihnea Zdrengea, **Ciprian Tomuleasa**. *Cancers*, 2021, in press. **impact factor: 6.126.**
36. EFFECTS OF LEUKEMIA SALIVA ON DENTAL RESIN-BASED COMPOSITES: AN IN VITRO ANALYSIS. Alexandru Mester, Marioara Moldovan, Stanca Cuc, **Ciprian Tomuleasa**, Sergiu Pasca, Miuta Filip, Andra Piciu, Florin Onisor. *Biomedicines*, 2021, in press. **impact factor: 6.081.**
37. THE THERAPEUTIC MANIPULATION OF IL-10 AND PROGRAMMED DEATH LIGAND-1 IN ACUTE MYELOID LEUKAEMIA: THE ADVANTAGE OF TARGETING BOTH PD-L1/PD-L2-PD-1 AND IL-10-IL-10R PATHWAYS. Laura Jimbu, Oana Mesaros, Alexandra Neaga, Ana Maria Nanut, **Ciprian Tomuleasa**, Delia Dima, Corina Bocsan, Mihnea Zdrengea. *Pharmaceuticals*, 2021, in press. **impact factor: 5.863.**
38. LOOKING AHEAD ON TARGETING MACROPHAGES BY CAR T- OR NK-CELLS. David Keyes, Paul Alexandru Milea, Andreea-Isabella Mazga, Adrian-Bogdan Țigu, Madalina Nistor, Diana Cenariu, Radu Tomai, Sanda Buruiana, Hermann Einsele, Alina Daniela Tănase, **Ciprian Tomuleasa**. *Expert Opinion of Therapeutic Targets* 2024, in press. **impact factor: 5.8.**
39. APPROACH TO THE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENT. Valentina Sas, Vlad Moisoiu, Patric Teodorescu, Sebastian Tranca, Laura Pop, Sabina Iluta, Sergiu Pasca, Cristina Blag, Sorin Man, Andrei Roman, Catalin Constantinescu, Ioana Rus, Mihail Buse, Cosmin Lisencu, Bogdan Fetica, Mirela Marian, Cristina Selicean, Ioana Berindan-Neagoe, Bobe Petrushev, Horia Bumbea, Alina Tanase, Mihnea Zdrengea, Shigeo Fuji, Shigehisa Kitano, **Ciprian Tomuleasa**, Romanian-Japanese Working Group of the Romanian Society for Bone Marrow Transplantation. *Journal of Clinical Medicine*, 2019, in press. **impact factor: 5.688.**
40. DIFFERENTIAL DIAGNOSIS OF MALIGNANT LYMPHADENOPATHY USING FLOW CYTOMETRY ON FINE NEEDLE ASPIRATION. REPORT ON 269 CASES. Carla Griesel, Minodora Desmirean, Tonya Esterhuizen, Sergiu Pasca, Bobe Petrushev, Cristina Selicean, Andrei Roman, Bogdan Fetica, Carmen Swanepoel, **Ciprian Tomuleasa**, Ravnit Grewal. *Journal of Clinical Medicine*, 2020, in press, **impact factor: 5.688.**
41. IN VIVO IMAGING SYSTEM (IVIS) THERAPEUTIC ASSESSMENT OF TYROSINE KINASE INHIBITOR LOADED GOLD ANOCARRIERS FOR ACUTE MYELOID LEUKEMIA. Raluca-Andrada Munteanu, Adrian Bogdan Tigu, Richard Feder, Andra-Sorina Tatar, Diana Gulei, **Ciprian Tomuleasa**, Sanda Boca. *Frontiers in Pharmacology* 2024, impact factor: 5.6, in press
42. MICRORNA-155-5P PLAYS A CRITICAL ROLE IN TRANSIENT LEUKEMIA OF DOWN SYNDROME BY TARGETING TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBERS. Valentina Sas, Sergiu Sas, Ancuta Jurj, Laura Pop, Liviuta Budisan, Hideki Muramatsu, Delia Dima, Patric Teodorescu, Sabina Iluta, Cristina Turcas, Anca Onaciu, Raluca Munteanu, Diana Gulei, Alina-Andreea Zimta,

- Alexander von Gamm, Cristina Blag, Gheorghe Popa, Smaranda Arghirescu, Margit Serban, Sorin Man, Mirela Marian, Cristian Berce, Anca Colita, Alina Tanase, Mihnea Zdrengea, Seiji Kojima, Diana Gulei, Yoshiyuki Takahashi, **Ciprian Tomuleasa**. Cellular Physiology and Biochemistry, 2020, in press. **impact factor: 5.5**.
43. UNDERSTANDING DNA EPIGENETICS BY MEANS OF RAMAN/SERS ANALYSIS FOR CANCER DETECTION APPLICATIONS. Luca David, Anca Onaciu, Valentin Toma, Rareş-Mario Borşa, Cristian Moldovan, Adrian-Bogdan Țigu, Diana Cenariu, Ioan Simon, Gabriela-Fabiola ŞtiuŃiuŃ, Eugen Carasevici, Brindusa Dragoi, **Ciprian Tomuleasa**, Rareş-IonuŃ ŞtiuŃiuŃ. Biosensors 2024, in press. **impact factor: 5.4**.
44. HODGKIN'S LYMPHOMA AND ITS ASSOCIATION WITH EBV AND HIV INFECTION. Grewal Ravnit, Alexandra Irimie, Naidoo Nasheen, Mohamed Nooroudien, Petrushev Bobe, Chetty Manogari, **Tomuleasa Ciprian**, Abayomi Emmanuel Akinola. Critical Reviews in Clinical Laboratory Sciences, in press. **impact factor: 5.340**.
45. A HYPOTHESIS OF TREATMENT STRATEGY OF SEVERE MULTICENTRIC CASTLEMAN'S DISEASE WITH CONTINUOUS RENAL REPLACEMENT THERAPY. Catalin Constantinescu, David Keyes, Vlad Moisoiu, Olga Grajdieru, Andrea Szekely, Evangelos Terpos, **Ciprian Tomuleasa**. Journal of Cellular and Molecular Medicine 2024, in press. **impact factor: 5.31**.
46. SINGLE, LOW DOSE DECITABINE AS FRONTLINE THERAPY OF ACUTE MYELOID LEUKEMIA, WITH VENETOCLAX SALVAGE. Ciprian Jitaru, Mareike Peters, Lovisha Aggarwal, Anamaria Bancos, Adrian Tigu, Diana Cenariu, Cristina Selicean, Sergiu Pasca, Vlad Moisoiu, Petra Rotariu, Maria Santa, Sabina Iluta, Rareş Drula, David Keyes, Aranka Kurtus, Mihnea Zdrengea, Lukasz Gondek, **Ciprian Tomuleasa**, Gabriel Ghiaur. Journal of Cellular and Molecular Medicine 2024, in press. **impact factor: 5.31**.
47. RNA METHYLATION SEQUENCING SHOWS DIFFERENT GENE EXPRESSION SIGNATURES FOR RESPONSE TO AZACYTIDINE THERAPY IN HIGH-GRADE MYELODYSPLASTIC SYNDROMES. Diana Gulei, Vlad Moisoiu, David Keyes, Rares Drula, Sabina Iluta, Adrian Bogdan Tigu, Madalina Nistor, Ciprian Jitaru, Anamaria Bancos, Petra Rotariu, Corina Popovici, Delia Dima, Radu Tomai, Ioana Rus, Catalin Constantinescu, Raluca Munteanu, Diana Cenariu, Ugur Sezerman, Mihnea Zdrengea, Jaroslav Cermak, Hermann Einsele, Gabriel Ghiaur, **Ciprian Tomuleasa**. Journal of Cellular and Molecular Medicine 2024, **impact factor: 5.259**, in press.
48. MAGNETIC RESONANCE IMAGING-BASED DIAGNOSIS OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY IN A PATIENT WITH NON-HODGKIN'S LYMPHOMA FOLLOWING THERAPY WITH CYCLOPHOSPHAMIDE, HYDROXYDAUNORUBICIN, VINCRISTINE, PREDNISON AND RITUXIMAB. Delia Dima, **Ciprian Tomuleasa**, Alexandru Irimie, Ioan Stefan Florian, Bobe Petrushev, Ioana Berindan-Neagoe, Andrei Cucuianu. Cancer. 2014;120(24):4005-6. **impact factor: 5.2**.
49. RNA SEQUENCING SUGGESTS THAT NON-CODING RNAs PLAY A ROLE IN THE DEVELOPMENT OF ACQUIRED HEMOPHILIA. Bogdan Tigu, Ionut Hotea, Cristina Blag, Rares Drula, Alina-Andreea Zimta, Noemi Dirzu, Maria Santa, Delia Dima, Jon Thor Bergthorsson, Victor Greiff, Margit Serban, Daniel Coriu, Diana Gulei,

- Johnny Mahlangu, **Ciprian Tomuleasa**. Journal of Cellular and Molecular Medicine, 2023, in press. impact factor: 5.295.
50. DESIGN AND PRECLINICAL TESTING OF AN ANTI-CD41 CAR T CELL FOR THE TREATMENT OF ACUTE MEGAKARYOBLASTIC LEUKEMIA. Adrian-Bogdan Tigu, Catalin Constantinescu, Patric Teodorescu, David Keyges, Richard Feder, Mareike Peters, Ioana Pralea, Cristina Iuga, Diana Cenariu, Andra Marcu, Alina Tanase, Anca Colita, Rares Drula, Jon Thor Bergthorsson, Victor Greiff, Delia Dima, Ioana Rus, Mihnea Zdrenghea, Diana Gulei, Gabriel Ghiaur, **Ciprian Tomuleasa**. Journal of Cellular and Molecular Medicine, 2023, in press. **impact factor: 5.295**.
51. CLINICAL APPROACH TO THE PATIENT IN CRITICAL CONDITION FOLLOWING IMMUNOTHERAPY AND/OR STEM CELL TRANSPLANTATION. GUIDELINE FOR THE ON-CALL PHYSICIAN. Catalin Constantinescu, Constantin Bodolea, Sergiu Pasca, Delia Dima, Ioana Rus, Tiberiu Tat, Patric Teodorescu, Patriciu Achimas-Cadariu, Alina Tanase, **Ciprian Tomuleasa**, Hermann Einsele. Journal of Clinical Medicine, 2019, in press. **impact factor: 5.306**.
52. SERS-BASED ASSESSMENT OF DNA METHYLATION FOR THE EVALUATION OF MRD IN ACUTE PROMYELOCYTIC LEUKEMIA. Anamaria Bancos, Stefania D. Iancu, Vlad Moisoiu, Alexandra Ghiaur, Adrian Bogdan Tigu, Cristina Buran, Georgiana Ion, Camelia Stancioaca, Bogdan Ionescu, Mihaela Dragomir, Codruta F. Buldus, Diana Cenariu, Madalina Nistor, Diana Gulei, David Keyges, Nicolae Leopold, Daniel Coriu, **Ciprian Tomuleasa**. Journal of Cellular and Molecular Medicine 2024, **impact factor: 5.259**, in press.
53. MECOM, HBS1L-MYB, THRB-RARB, JAK2 and TERT polymorphisms defining predisposition to myeloproliferative neoplasms - a study on 939 patients. Adrian Trifa, Claudia Banescu, Anca Bojan, Alina Popa, Florin Tripon, Delia Dima, Viola Maria Popov, Stefan Vesa, Mihaela Andreescu, Tunde Torok-Vistai, Romeo Mihaila, Nicoleta Berbec, Ion Macarie, Andrei Colita, Maria Iordache, Alina Catana, Marius Farcas, **Ciprian Tomuleasa**, Kinga Vasile, Cristina Truica, Adriana Todinca, Lavinia Munteanu, Raluca Manolache, Horia Bumbea, Ana-Maria Vladareanu, Mihaela Dervesteanu, Cristina Ciufu, Radu Popp. American Journal of Hematology 2017, in press. **impact factor: 5.275**.
54. SERS LIQUID BIOPSY: AN EMERGING TOOL FOR MEDICAL DIAGNOSIS. Vlad Moisoiu, Stefania Dana Iancu, Andrei Stefancu, Tudor Moisoiu, Barbara Pardini, Mihnea Paul Dragomir, Nicolae Crisan, Lucretia Avram, Dana Crisan, Iulia Andras, Daniela Fodor, Carmen Socaciu, Zoltán Bálint, **Ciprian Tomuleasa**, Nicolae Leopold, Florin Elec. Colloids and Surfaces B: Biointerfaces, 2021, in press. **impact factor: 5.268**.
55. HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACUTE PROMYELOCYTIC LEUKEMIA IN THE ATRA/ATO ERA. Andrei Colita, Alina Daniela Tanase, **Ciprian Tomuleasa**, Anca Colita. Cancers 2023, **impact factor: 5.2**, in press.
56. EXPLORING THERAPEUTIC AVENUES IN LUNG CANCER: THE EPIGENETIC PERSPECTIVE. Raluca Munteanu, **Ciprian Tomuleasa**, Cristina Adela Iuga, Diana Gulei, Tudor Eliade Ciuleanu. Cancers 2023, in press. **impact factor: 5.2**.
57. MOLECULAR SUBTYPES AND THE ROLE OF TP53 IN DIFFUSE LARGE B-CELL LYMPHOMA AND RICHTER SYNDROME. Ivan Negara, **Ciprian Tomuleasa**, Sanda Buruiana, Dimitar G. Efremov. Cancers 2024, **impact factor: 5.2**, in press

58. ASSESSING MEASURABLE RESIDUAL DISEASE IN CHRONIC MYELOID LEUKEMIA. BCR-ABL IS IN THE *AVANT-GARDE* OF MOLECULAR HEMATOLOGY. Vlad Moisoiu, Delia Dima, Lorand Parajdi, Sergiu Pasca, Patric Teodorescu, Radu Precup, **Ciprian Tomuleasa**, Simona Soverini. *Frontiers in Oncology*, 2019, in press, **impact factor: 5.165**.
59. LET'S TALK ABOUT BITES AND OTHER DRUGS IN THE REAL LIFE SETTING FOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA. Dalma Deak, Cristina Pop, Andreea-Alina Zimta, Ancuta Jurj, Alexandra Ghiaur, Sergiu Pasca, Delia Dima, Patric Teodorescu, Catalin Constantinescu, Mihnea Zdrengea, Daniel Coriu, Alina Tanase, Ioana Berindan-Neagoe, Delia Dima, Hermann Einsele, **Ciprian Tomuleasa**. *Frontiers in Immunology*, 2019, in press. **impact factor: 5.165**.
60. BASOPHILIA SUGGESTS AN 'ACCELERATED PHASE' IN THE EVOLUTION OF CHRONIC CALR-POSITIVE PRIMARY MYELOFIBROSIS TOWARDS ACUTE MYELOID LEUKEMIA. Jerome Dobrowolski, Sergiu Pasca, Patric Teodorescu, Ioana Rus, Cristina Selicean, Ana Maria Rosu, Ioana Berindan-Neagoe, Bogdan Fetica, Adrian Trifa, Anca Bojan, Mihnea Zdrengea, Bobe Petrushev, **Ciprian Tomuleasa**, Delia Dima. *Frontiers in Oncology*, 2019, in press, **impact factor: 5.165**.
61. LEAM *VERSUS* BEAM *VERSUS* CLV CONDITIONING REGIMEN FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN RELAPSED/REFRACTORY LYMPHOMAS. RETROSPECTIVE COMPARISON OF TOXICITY AND EFFICACY ON 222 PATIENTS, ON BEHALF OF THE ROMANIAN SOCIETY FOR BONE MARROW TRANSPLANTATION. Andrei Colita, Anca Colita, Horia Bumbea, Adina Croitoru, Carmen Orban, Lavinia Eugenia Lipan, Oana Gabriela Craciun, Dan Soare, Cecilia Ghimici, Raluca Manolache, Ionel Gelatu, Ana Maria Vladareanu, Patric Teodorescu, Delia Dima, Sergiu Pasca, Anca Lupu, Daniel Coriu, **Ciprian Tomuleasa**, Alina Tanase. *Frontiers in Oncology* 2019; in press. **impact factor: 5.165**.
62. PROTEIN DYSREGULATION IN GRAFT-VERSUS-HOST DISEASE FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES. Liren Qian, Delia Dima, Jian Cen, Cristian Berce, Lajos Raduly, Alina Tanase, Bobe Petrushev, Ioana Berindan-Neagoe, Alexandru Irimie, Ancuta Jurj, Jian Liang Shen, **Ciprian Tomuleasa**. *Oncotarget*, in press. **impact factor: 5.168**.
63. GENETICALLY ENHANCED T LYMPHOCYTES AND THE INTENSIVE CARE UNIT. Tiberiu Tat, Huming Li, Catalin Constantinescu, Anca Onaciu, Sergiu Chira, Sergiu Pasca, Bobe Petrushev, Vlad Moisoiu, Wilhelm-Thomas Micu, Cristian Berce, Sebastian Tranca, Delia Dima, Ioana Berindan-Neagoe, Jianliang Shen, **Ciprian Tomuleasa**, Liren Qian. *Oncotarget* 2018, in press. **impact factor: 5.168**.
64. MOBILE HEALTH TECHNOLOGY FOR THE PERSONALIZED THERAPY OF HEMOPHILIA. [Noemi Dirzu](#), Ionut Hotea, Melen Brinza, Mareike-Catrina Peters, Krisztina Gal, Louis Popescu, Cristina Blag, Mirela Marian, Eva Pal, Marilena Stanescu, [Diana](#) Cenariu, Cristina Tarniceriu, Margit Serban, Delia Dima, Daniel Coriu, [Ciprian Tomuleasa](#). *Frontiers in Medicine*, 2021, in press, **impact factor: 5.091**.
65. COAGULOPATHY IN ACUTE PROMYELOCYTIC LEUKEMIA: CAN WE GO BEYOND SUPPORTIVE CARE? Bryan C. Hambley, **Ciprian Tomuleasa**, Gabriel Ghiaur. *Frontiers in Medicine*, 2021, in press. **impact factor: 5.091**.
66. MODERN APPROACHES TO HEMOPHILIA MANAGEMENT: GENE THERAPY AND BEYOND. Daniel Coriu, Noemi Dirzu, Alina-Andreea Zimta, Bryan C. Hambley,

- Laszlo Nemes, Xiaojing Liu, Gabriel Ghiaur, Johny Mahlangu, **Ciprian Tomuleasa**. *Frontiers in Medicine*, 2022, in press. **impact factor: 5.091**.
67. RESULTS OF A TWO-ARM PHASE II CLINICAL TRIAL USING POST-TRANSPLANTATION CYCLOPHOSPHAMIDE FOR PREVENTION OF GRAFT-VERSUS-HOST DISEASE IN HAPLOIDENTICAL AND MISMATCHED UNRELATED DONORS HEMATOPOIETIC STEM CELL TRANSPLANTATION. Sameh Gaballa, Isabell Ge, Riad El-Fakih, Jonathan E. Brammer, **Ciprian Tomuleasa**, Sa A. Wang, Dean Lee, Demetrios Petropoulos, Kai Cao, Gabriela Rondon, Julianne Chen, Aimee Hammerstrom, Lindsey Lombardi, Gheath Al-atrash, Martin Korbling, Oran Betul, Partow Kebriaei, Sairah Ahmed, Nina Shah, Katyoun Rezvani, David Marin, Qaiser Bashir, Amin Alousi, Yago Nieto, Muzaffar Qazilbash, Chitra Hosing, Uday Popat, Elizabeth J. Shpall, Issa Khouri, Richard E. Champlin, Stefan O. Ciurea. *Cancer*, 2016; 122(21):3316-3326. **impact factor 5.068**.
68. EDITORIAL: FLOW CYTOMETRY – A POWERFUL TOOL FOR DIAGNOSIS AND THERAPY MONITORING IN HEMATOLOGY AND IMMUNOLOGY. Cenariu M, Grewal R, Bumbea H, Sauma D, Tomuleasa C. *Frontiers in Medicine* 2023, in press, **impact factor: 5.058**.
69. EXOSOME-CARRIED MICRORNA-BASED SIGNATURE AS A CELLULAR TRIGGER FOR THE EVOLUTION OF CHRONIC LYMPHOCYTIC LEUKEMIA INTO RICHTER SYNDROME. Ancuta Jurj, Laura Pop, Bobe Petrushev, Delia Dima, Ioana Rus, Adrian Trifa, Bogdan Fetica, Grigore Gafencu, Sonia Selicean, Daiana Temian, Cristian Berce, Alexandra Sacu, Alin Moldovan, Andrei Colita, Horia Bumbea, Alina Tanase, Angela Dascalescu, Nicolae Leopold, Emil Burzo, Mihnea Zdrengea, Rares Stiufiuc, **Ciprian Tomuleasa**, Ioana Berindan-Neagoie. *Critical Reviews in Clinical Laboratory Sciences*, 2018, in press. **impact factor: 5.34**.
70. PERIODONTAL DISEASE MIGHT BE A RISK FACTOR FOR GRAFT VERSUS HOST DISEASE. A SYSTEMATIC REVIEW. Alexandru Mester, Andra Mester, Sebastian Tranca, **Ciprian Tomuleasa**, Alina Tanase. *Critical Reviews in Hematology and Oncology*, 2020, in press. **impact factor: 5.012**.
71. PROGRESS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION AND CELLULAR THERAPIES. Diana Cenariu, Horia Bumbea, Anca Colita, Catalin Constantinescu, Minodora Desmirean, Sabina Iluta, Daniel Lysak, Alberto Mussetti, Ioana Tichil, Alina Tanase, **Ciprian Tomuleasa**. *Journal of Clinical Medicine*, 2022, in press. **impact factor: 4.964**.
72. HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS AND SUBSEQUENT ACUTE HEPATIC FAILURE IN A MULTIPLE MYELOMA PATIENT FOLLOWING COMBINATION THERAPY WITH IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE. Catalin Constantinescu, Bobe Petrushev, Ioana Rus, Horia Stefanescu, Otilia Frasinariu, Simona Margarit, Delia Dima, **Ciprian Tomuleasa**. *Journal of Personalized Medicine*, 2022, in press. **impact factor: 4.945**
73. MEDICAL APPLICATIONS OF HYDROGEN IN HEMATOLOGICAL DISEASES. Liren Qian, Zhengcheng Wu, Jian Cen, Sergiu Pasca, **Ciprian Tomuleasa**. *Oxidative Medicine and Cellular Longevity*, 2019, in press. **impact factor: 4.868**.
74. SYBERGISTIC EFFECT OF HUMAN CHORIONIC GONADOTROPIN AND GRANULOCYTE COLONY STIMULATING FACTOR IN THE MOBILIZATION OF HSCS IMPROVES OVERALL SURVIVAL AFTER PBSCT IN A PRECLINICAL

- MURINE MODEL. ARE WE FAR ENOUGH FOR THERAPY ? Cismaru Cosmin-Andrei, **Tomuleasa Ciprian**, Jurj Ancuta, Chira Sergiu, Isacescu Ecaterina, Cismaru Gabriel, Gherman Madalina, Tomuleasa Diana, Muntean Raluca, Berindan-Neogoe Ioana. Stem Cell Reviews and Reports, 2023, **impact factor: 4.8**, in press.
75. OPTIMIZATION OF TYROSINE KINASE INHIBITOR-LOADED GOLD NANOPARTICLES FOR STIMULI-TRIGGERED ANTILEUKEMIC DRUG RELEASE. Andra-Sorina Tatar, Timea Nagy-Simon, Adrian Bogdan Tigu, **Ciprian Tomuleasa**, Sanda Boca. Journal of Functional Biomaterials., 2023, **impact factor: 4.8**.
76. MACROPHAGE POLARIZATION IN CHRONIC LYMPHOCYTIC LEUKEMIA: NURSE-LIKE CELLS ARE THE CARETAKERS OF CLL CELLS. Oana Mesaros, Laura Jimbu, Alexandra Neaga, Cristian Marian Popescu, Iulia Berceanu, **Ciprian Tomuleasa**, Bogdan Fetica, Mihnea T. Zdrenghia. Biomedicine, 2020, submitted for publication. **impact factor: 4.717**.
77. MICRORNA 155 IMPLICATION IN M1 POLARIZATION. THE IMPACT IN INFLAMMATORY DISEASES. Sergiu Pasca, Maria-Ancuta Jurj, Bobe Petrushev, **Ciprian Tomuleasa**, Dana Matei. Frontiers in Immunology, **impact factor: 4.716**.
78. MICRORNA 155 IMPLICATION IN M1 POLARIZATION. THE IMPACT IN INFLAMMATORY DISEASES. Sergiu Pasca, Maria-Ancuta Jurj, Bobe Petrushev, **Ciprian Tomuleasa**, Dana Matei. Frontiers in Oncology 2020, in press, **impact factor: 4.716**.
79. EXPLORING NOVEL FRONTIERS IN CANCER THERAPY. Bogdan Tigu, **Ciprian Tomuleasa**. Biomedicines 2024, **impact factor : 4.7**.
80. TRANSFORMING GROWTH FACTOR BETA-MEDIATED MICROMECHANICS MODULATES DISEASE PROGRESSION IN PRIMARY MYELOFIBROSIS. Patric Teodorescu, Sergiu Pasca, Ancuta Jurj, Jon Petur Joelsson, Sonia Selicean, Cristian Moldovan, Raluca Munteanu, Anca Onaciu, Mihail Buse, Bogdan Tigu, Sebastian Rauch, Rares Stiufiuc, Minodora Desmirean, Delia Dima, Jon Thor Bergthorsson, Bobe Petrushev, Cristian Berce, Stefan Ciurea, Gabriel Ghiaur, **Ciprian Tomuleasa**. Journal of Cellular and Molecular Medicine, 2020, in press, **impact factor 4.658**.
81. AZACYTIDINE PLUS OLAPARIB FOR RELAPSED ACUTE MYELOID LEUKEMIA, INELIGIBLE FOR INTENSIVE CHEMOTHERAPY, DIAGNOSED WITH A SYNCHRONOUS MALIGNANCY. Sabina Iluta, Ancuta Jurj, Grigore Gafencu, Sergiu Pasca, Andreea Terec, Patric Teodorescu, Cristina Selicean, Ciprian Jitaru, Maria Iordache, Catalin Constantinescu, Richard Feder, Raluca Munteanu, Delia Dima, Diana Gulei, Tudor Ciuleanu, **Ciprian Tomuleasa**. Journal of Cellular and Molecular Medicine, 2021, in press. **impact factor: 4.486**.
82. ALLOGENEIC STEM CELL TRANSPLANTATION FOR ADULT T-CELL LEUKEMIA/LYMPHOMA – ROMANIAN EXPERIENCE. Alina D. Tanase, Andrei Colita, Oana G. Craciun, Lavinia Lipan, Zsofia Varady, Laura Stefan, Adela Ranate, Sergiu Pasca, Horia Bumbea, Mihaela Andreescu, Viola Popov, Alexandru Bardas, Daniel Coriu, Anca Roxana Lupu, **Ciprian Tomuleasa**, Anca Colita, Olivier Hermine. Journal of Clinical Medicine, 2020, in press. **impact factor: 4.674**.
83. DATABASE-GUIDED ANALYSIS FOR IMMUNOPHENOTYPIC DIAGNOSIS AND FOLLOW-UP OF ACUTE MYELOID LEUKEMIA WITH RECURRENT GENETIC ABNORMALITIES. [Carmen-Mariana Aanei](#), [Richard Veyrat-Masson](#), Cristina Selicean, Mirela Marian, Lauren Rigollet, Adrian Pavel Trifa, [Ciprian](#)

[Tomuleasa](#), Adrian Serban, Mohamad Cherry, [Pascale Flandrin-Gresta](#), [Emmanuelle Tavernier](#), [Denis Guyotat](#)-Catafal. *Frontiers in Oncology*, 2021, in press. **impact factor: 4.448.**

84. FLOW CYTOMETRY OF CD5-POSITIVE HAIRY CELL LEUKEMIA. Diana Cenariu, Ioana Rus, Jon Thor Bergthorsson, Ravnit Grewal, Mihai Cenariu, Victor Greiff, Bogdan Tigu, Delia Dima, Cristina Selicean, Bobe Petrushev, Mihnea Zdrenghea, Jonathan Fromm, **Ciprian Tomuleasa**. *Molecular Diagnosis and Therapy* 2023, in press. **impact factor: 4.476.**
85. TET2 RS1548483 NSP ASSOCIATING WITH SUSCEPTIBILITY TO MOLECULARLY ANNOTATED POLYCYTHEMIA VERA AND PRIMARY MYELOFIBROSIS. Diana Lighezan, Anca Bojan, Mihaela Iancu, Raluca Pop, Ștefana Gligor-Popa, Florin Tripon, Adriana Cosma, **Ciprian Tomuleasa**, Delia Dima, Mihnea Zdrenghea, Bogdan Fetica, Ioana Ioniță, Ildikó Gaál, Simona Vișan, Andreea-Manuela Mirea, Radu Popp, Mira Florea, Cătălin Araniciu, Lucian Petrescu, Ioan Pop, Claudia Bănescu, Adrian Trifa. *Journal of Personalized Medicine* in press. **impact factor: 4.433.**
86. LONG NON-CODING RNAs IN MYELOID MALIGNANCIES. Alina-Andreea Zimta, **Ciprian Tomuleasa**, George Calin, Ioana Berindan-Neagoe, *Frontiers in Oncology*, 2019, in press. **impact factor: 4.416.**
87. KRAS/NRAF/BRAF MUTATIONS AS POTENTIAL TARGETS IN MULTIPLE MYELOMA. Sergiu Pasca, **Ciprian Tomuleasa**, Gabriel Ghiaur, Patric Teodorescu, Delia Dima, Vlad Moisoiu, Cristian Berce, Cristina Stefan, Aaron Ciechanover, Hermann Einsele. *Frontiers in Oncology*, 2019, in press. **impact factor: 4.416.**
88. CURRENT THERAPEUTICS IN THE MANAGEMENT OF HEMOPHILIA – A CONSENSUS VIEW BY THE ROMANIAN SOCIETY OF HEMATOLOGY. Ionut Hotea, Melen Brinza, Cristina Blag, Alina-Andreea Zimta, Noemi Dirzu, Ioana Rus, Dragos Apostu, Horea Benea, Mirela Marian, Alexandru Mester, Sergiu Pasca, Sabina Ioana Iluta, Patric Teodorescu, Ciprian Jitaru, Mihnea Zdrenghea, Anca Bojan, Tunde Torok-Vistai, Radu Niculescu, Cristina Tarniceriu, Delia Dima, Margit Serban, **Ciprian Tomuleasa**, Daniel Coriu. *Annals of Translational Medicine*, 2021, in press. **impact factor: 4.421.**
89. EXTRAMEDULLARY HEMATOPOIESIS OF THE LIVER AND SPLEEN. Diana Cenariu, Sabina Iluta, Alina-Andreea Zimta, Bobe Petrushev, Liren Qian, Noemi Dirzu, **Ciprian Tomuleasa**, Horia Bumbea, Florin Zaharie. *Journal of Clinical Medicine*, 2021, in press, **impact factor: 4.241.**
90. SERS-BASED DNA METHYLATION PATTERN FOR THE POINT-OF-CARE DIFFERENTIAL DIAGNOSIS OF MALIGNANT LYMPHADENOPATHY. INITIAL ASSESSMENT COMPARING REACTIVE LYMPH NODES, B-CELL LYMPHOMAS, T-CELL LYMPHOMAS AND METASTATIC MELANOMA. Andrei Stefanu, Vlad Moisoiu, Stefania D. Iancu, Minodora Desmirean, Bobe Petrushev, Ancuta Jurj, Liviuta Budisan, Bogdan Fetica, Andrei Roman, Gina Dobie, Cristina Turcas, Mihnea Zdrenghea, Patric Teodorescu, Sergiu Pasca, Doina Piciu, Delia Dima, Nicolae Leopold, **Ciprian Tomuleasa**. *Colloids and Surfaces B: Biointerfaces*, in press. **impact factor: 4.389.**
91. GOLD NANOPARTICLES ENHANCE THE EFFECT OF TYROSIN KINASE INHIBITORS IN ACUTE MYELOID LEUKEMIA THERAPY. Bobe Petrushev, Sanda Boca, Timea Simon, Cristian Berce, Ioana Frinc, Delia Dima, Sonia Selicean, Grigore-

- Aristide Gafencu, Alina Tanase, Mihnea Zdrenghea, Adrian Florea, Sorina Suarasan, Liana Dima, Raluca Stanciu, Ancuta Jurj, Anca Buzoianu, Andrei Cucuianu, Simion Astilean, Alexandru Irimie, **Ciprian Tomuleasa**, Ioana Berindan-Neagoe. *International Journal of Nanomedicine*, 2016; 11:641-60. **impact factor: 4.383.**
92. IN VIVO ASSESSMENT OF BONE MARROW TOXICITY FOR GOLD NANOPARTICLE-BASED BIOCONJUGATES IN CRL:CD1(ICR) MICE. Cristian Berce, Ciprian Lucan, Bobe Petrushev, Sanda Boca, Mirela Miclean, Orsolya Sarpataki, Simion Astilean, Anca Buzoianu, **Ciprian Tomuleasa**, Anca Bojan. *International Journal of Nanomedicine*, 2016; 11:4261-73. **impact factor: 4.383.**
93. STRUCTURAL CHANGES OF RESIN BASED COMPOSITES IN SALIVA OF PATIENTS WITH LEUKEMIA BEFORE STARTING CHEMOTHERAPEUTIC REGIMEN. Alexandru Mester, Marioara Moldovan, Stanca Cuc, Ioan Petean, **Ciprian Tomuleasa**, Andra Piciu, Cristian Dinu *, Simion Bran, Florin Onisor. *Polymers*, 2022, in press. **impact factor: 4.329.**
94. IBRUTINIB MONOTHERAPY AS BRIDGE-TO-TRANSPLANT FOR RELAPSED/REFRACTORY PRIMARY OCULO-CEREBRAL LYMPHOMAS. ROMANIAN EXPERIENCE. Dalma Deak-Mihaly, Sabina Iluta, Sergiu Pasca, Ciprian Jitaru, Andrei Roman, Alexandra Andries, Monica Padurariu-Covit, Anca Vasilache, Anca Bojan, Angela Dascalescu, Ion Antohe, Anca Colita, Andrei Colita, Delia Dima, Alina Tanase, **Ciprian Tomuleasa**. *Journal of Clinical Medicine*, 2021, in press. **impact factor: 4.241.**
95. THE PREDICTIVE ROLE OF MODIFIED EARLY WARNING SCORES IN 174 HEMATOLOGICAL PATIENTS AT RISK FOR TRANSFER TO THE INTENSIVE CARE UNIT. Catalin Constantinescu, Sergiu Pasca, Sabina Iluta, Grigore Gafencu, Maria Santa, Ciprian Jitaru, Patric Teodorescu, Delia Dima, Mihnea Zdrenghea, **Ciprian Tomuleasa**. *Journal of Clinical Medicine*, 2021, in press, **impact factor: 4.241.**
96. EDITORIAL: NOVEL DRUGS TARGETING THE MICROENVIRONMENT AND THE EPIGENETIC CHANGES IN HEMATOPOIETIC MALIGNANCIES. Diana Gulei, **Ciprian Tomuleasa**, Liren Qian, Cristina Bagacean, Carlo M. Croce, Gabriel Ghiaur. *Frontiers in Pharmacology* 2020, in press. **impact factor: 4.225.**
97. NANOPHARMACOLOGY IN TRANSLATIONAL HEMATOLOGY AND ONCOLOGY. **Ciprian Tomuleasa**, Cornelia Braicu, Alexandra Irimie, Lucian Craciun, Ioana Berindan-Neagoe. [Int J Nanomedicine](#). 2014;9:3465-79. **impact factor: 4.195.**
98. REVERSING CHEMORESISTANCE OF MALIGNANT GLIOMAS STEM CELLS USING GOLD NANOPARTICLES. Anamaria Orza, Olga Soritau, **Ciprian Tomuleasa**, Liliana Olenic, Adrian Florea, Ovidiu Pana, Ioan Bratu, Eموke Pall, Stefan Florian, Dan Casciano, Alexandru S. Biris. *International Journal of Nanomedicine* 2013, 8:1-14. **impact factor: 4.195**
99. SORAFENIB FOR THE TREATMENT OF SOLID MALIGNANCIES. WHAT ABOUT THE CANCER MICROENVIRONMENT? **Tomuleasa C**, Cucuianu A, Aldea M, Berindan-Neagoe I. *International Journal of Nanomedicine*. 2013; 8:4043-4. **impact factor: 4.195.**
100. MRI-BASED IDENTIFICATION OF UNDIFFERENTIATED CELLS. LOOKING AT THE TWO FACES OF JANUS. **Tomuleasa C**, Florian IS, Berce C, Irimie A, Berindan-Neagoe I, Cucuianu A. *International Journal of Nanomedicine* 2014, 9:865-6. **impact factor: 4.195.**

101. DOSE INTENSITY AND AUTOLOGOUS STEM CELL TRANSPLANTATION AS SALVAGE THERAPY FOR PEDIATRIC CNS MALIGNANCIES. Seiji Kojima, Andrei Cucuianu, Yoshiyuki Takahashi, Ioana Berindan-Neagoe, Ioan Stefan Florian, **Ciprian Tomuleasa**. International Journal of Nanomedicine 2014, 9:3247-8. **impact factor: 4.195.**
102. SMALL MOLECULES AGAINST B-RAF (BRAF) VAL600GLU (V600E) SINGLE MUTATION. Florin Zaharie, Roxana Cojocneanu-Petric R, Mihai Muresan, Ioana Frinc, Delia Dima, Bobe Petrushev, Alina Tanase, Cristian Berce, Mariana Chitic, Ioana Berindan-Neagoe, Valentina Pileczki, Alexandru Irimie, **Ciprian Tomuleasa**. International Journal of Nanomedicine 2015, 9:3247-8. **impact factor: 4.195.**
103. THE MALIGNANT ROLE OF EXOSOMES AS NANOCARRIERS OF RARE RNA SPECIES. Alina-Andreea Zimta, Olafur Eysteinn Sigurjonsson, Diana, **Ciprian Tomuleasa**. International Journal of Molecular Sciences, 2020, in press. **impact factor: 4.183.**
104. FIBROBLAST DYNAMICS AS AN IN VITRO SCREENING PLATFORM FOR ANTI-FIBROTIC DRUGS IN PRIMARY MYELOFIBROSIS. **Ciprian Tomuleasa**, Sonia Selicean, Grigore Gafencu, Bobe Petrushev, Daiana Temian, Laura Pop, Cristian Berce, Ancuta Jurj, Adrian Trifa, Ana Maria Rosu, Sergiu Pasca, Lorand Magdo, Delia Dima, Mihnea Zdrenghea, Ioana Frinc, Anca Bojan, Alina Tanase, Ioana Berindan-Neagoe, Gabriel Ghiaur, Stefan Ciurea. Journal of Cellular Physiology 2018, in press. **impact factor: 4.155.**
105. DAY 15 AND DAY 33 MINIMAL RESIDUAL DISEASE ASSESSMENT FOR ACUTE LYMPHOBLASTIC LEUKEMIA TREATED ACCORDING TO THE BFM ALL IC 2009 PROTOCOL. SINGLE-CENTER EXPERIENCE OF 133 CASES. Letitia Elena Radu, Sergiu Pasca, Andrei Colita, **Ciprian Tomuleasa**, Codruta Popa, Catalin Serban, Anca Gheorghe, Andreea Serbanica, Cristina Jercan, Andra Marcu, Ana Bica, Patric Teodorescu, Catalin Constantinescu, Bobe Petrushev, Minodora Asan, Cerasela Jardan, Mihaela Dragomir, Alina Tanase, Anca Colita. Frontiers in Oncology, 2020, in press, **impact factor: 4.137.**
106. SERS-BASED ASSESSMENT OF MRD IN ACUTE PROMYELOCYTIC LEUKEMIA? Cristina Turcas, Vlad Moisoiu, Andrei Stefancu, Ancuta Jurj, Stefania D. Iancu, Patric Teodorescu, Sergiu Pasca, Anca Bojan, Adrian Trifa, Sabina Iluta, Andreea Zimta, Bobe Petrushev, Mihnea Zdrenghea, Horia Bumbea, Daniel Coriu, Delia Dima, Nicolae Leopold, **Ciprian Tomuleasa**. Frontiers in Oncology, in press. **impact factor: 4.137.**
107. CD19-TARGETED, RAMAN-TAGGED GOLD NANOURCHINS AS THERANOSTIC AGENTS AGAINST ACUTE LYMPHOBLASTIC LEUKEMIA. Andra-Sorina Tatar, Ancuta Jurj, **Ciprian Tomuleasa**, Adrian Florea, Ioana Berindan-Neagoe, Dana Cialla-May, Juergen Popp, Simion Astilean, Sanda Boca. Colloids and Surfaces B: Biointerfaces, 2019, in press. **impact factor: 3.997.**
108. CHARACTERIZATION OF EXTRACHROMOSOMAL CIRCULAR DNA IN PATIENTS WITH ACUTE MYELOID LEUKEMIA. PROOF-OF-CONCEPT REPORT USING COHORTS FROM BEIJING AND SHANGHAI. Liren Qian, Xinxin Xia, Jiaxin Liu, Xiaoping Chen, Yu Liu, Xiaona Wang, Sabina Iluta, Sergiu Pasca, Diana Gulei, Ciprian Tomuleasa. Annals of Translational Medicine, 2022, in press. **impact factor: 3.932.**

109. USE OF VENO-VENOUS HEMODIAFILTRATION AS RENAL REPLACEMENT THERAPY FOR SEVERE TUMOR LYSIS SYNDROME. Radu Tomai, Antonia Oancea, Ciprian Tomuleasa, Delia Dima. *Diagnostics* 2024, submitted for publication. **impact factor: 3.992.**
110. THE NON-MUTATIONAL CAUSES OF HEMOPHILIA: NON-CODING RNAS AND ACQUIRED HEMOPHILIA. Alina-Andreea Zimta, Ionut Hotea, Melen Brinza, Cristina Blag, Sabina Iluta, Catalin Constantinescu, Atamyrat Bashimov, Elisabeth-Antonia Marchis-Hund, Alexandra Coudsy, Laetitia Muller-Mohnssen, Noemi Dirzu, Diana Gulei, Delia Dima, Margit Serban, Daniel Coriu, **Ciprian Tomuleasa**. *Frontiers in Medicine*, 2021, **impact factor: 3.9**, in press.
111. RARE WITHIN RARE: A GIRL WITH SEVERE HAEMOPHILIA A AND TURNER SYNDROME. Cristina Blag, Margit Serban, Cristina Emilia Ursu, Cristina Popa, Adina Traila, Cristian Jinca, **Ciprian Tomuleasa**, Mădălina Bota, Smaranda Teodora Arghirescu. *Journal of Clinical Medicine* 2023, in press. **impact factor: 3.9.**
112. ANESTHESIA MANAGEMENT FOR GIANT INTRAABDOMINAL TUMORS: A CASE SERIES STUDY. Olga Grajdieru, Cristina Petrisor, Constantin Bodolea, **Ciprian Tomuleasa**, Catalin Constantinescu. *Journal of Clinical Medicine* 2024, in press. **impact factor: 3.9.**
113. ERYTHROPOIESIS: THE ROLE OF SIGNALLING PATHWAYS, GENETIC AND EPIGENETIC REGULATORS. Ioana Tichil, Ileana Mitre, Anca Bojan, Mihnea Zdrenghea, **Ciprian Tomuleasa**, Diana Cenariu. *Journal of Clinical Medicine* 2024, **impact factor: 3.9**, in press.
114. ADVANCES IN CELL AND IMMUNE THERAPIES FOR MELANOMA. Tanase Timis, Sanda Buruiana, Delia Dima, Madalina Nistor, Ximena Maria Muresan, Diana Cenariu, Adrian-Bogdan Tigu, **Ciprian Tomuleasa**. *Biomedicines* 2025, in press. **impact factor: 3.9.**
115. INSIGHTS INTO PEDIATRIC GATA2-RELATED MDS. UNVEILLING CHALLENGES IN CLINICAL PRACTICE. Andra Daniela Marcu, Ana Maria Bica, Cristina Georgiana Jercan, Letitia Elena Radu, Andreea Nicoleta Serbanica, Dumitru Jordan, Andrei Colita, Simona Olimpia Dima, Ciprian Tomuleasa, Alina Daniela Tanase, Anca Colita. *Biomedicines* 2025, **impact factor : 3.9.** in press.
116. THE ROLE OF PATHOLOGY DEPARTMENT IN THE PRE-ANALYTICAL PHASE OF MOLECULAR ANALYSES. Sergiu Susman, Ioana Berindan-Neagoe, Bobe Petrushev, Radu Pirlog, Ioan-Stefan Florian, Carmen-Mihaela Mihiu, Cristian Berce, Lucian Craciun, Ravnit Grewal, **Ciprian Tomuleasa**, *Cancer Management and Research*, in press, **impact factor: 3.851.**
117. TARGETING THE MICROENVIRONMENT IN MDS: THE FINAL FRONTIER. Patric Teodorescu, Sergiu Pasca, Delia Dima, **Ciprian Tomuleasa**, Gabriel Ghiaur. *Frontiers in Pharmacology* 2020, in press. **impact factor: 3.845.**
118. TARGETING THE MICROENVIRONMENT IN MDS: THE FINAL FRONTIER. Patric Teodorescu, Sergiu Pasca, Delia Dima, **Ciprian Tomuleasa**, Gabriel Ghiaur. *Frontiers in Pharmacology* 2020, in press. **impact factor: 3.845.**
119. A NARRATIVE VIEW OF CENTRAL NERVOUS SYSTEM INVOLVEMENT IN ACUTE LEUKEMIAS. Dalma Deak, Nicolae Gorcea-Andronic, Valentina Sas, Patric Teodorescu, Sabina Iluta, Sergiu Pasca, Ionut Hotea, Cristina Turcas, Simona Galdean, Jakob Steinheber, Ioana Rus, Sebastian Rauch, Raluca Munteanu, Ancuta Jurj, Bobe

- Petrushev, Cristina Selicean, Mirela Marian, Olga Soritau, Alexandra Andries, Andrei Roman, Delia Dima, Alina Tanase, **Ciprian Tomuleasa**. *Annals of Translational Medicine*, 2021, in press, **impact factor: 3.689**.
120. USEFULNESS OF SALINE SEALING IN PREVENTING PNEUMOTHORAX AFTER CT-GUIDED BIOPSIES OF THE LUNG. Andrei Roman, Andreea Brozba, Alexandru Necula, Delia Doris Muntean, Paul Kubelac, Zsolt Fekete, **Ciprian Tomuleasa**, Csaba Csutak, Diana, Feier, Roxana Pintican, Catalin Vlad. *Diagnostics* 2023, in press. **impact factor: 3.61**.
121. NANOSCLAE INVESTIGATION OF DNA DEMETHYLATION IN LEUKEMIA CELLS BY MEANS OF ULTRASENSITIVE VIBRATIONAL SPECTROSCOPY. Anca Onaciu, Valentin Toma, Cristian Moldovan, Adrian Bogdan Țigu, Diana Cenariu, Carina Culic, Rareș Mario Borșa, Luca David, Gabriela Fabiola Știuțiuț, Romulus Tetean, **Ciprian Tomuleasa**, Rareș Ionuț Știuțiuț. *Sensors*, 2022, in press. **impact factor: 3.576**.
122. COVID-19 IMPACT ON CHRONIC MYELOID LEUKEMIA PATIENTS. Dana Raluca Arbore, Simona Maria Galdean, Delia Dima, Ioana Rus, David Kegyes, Raluca Geanina Ababei, Daniela Dragancea, Radu Andrei Toma, Adrian Pavel Trifa, **Ciprian Tomuleasa**. *Journal of Personalized Medicine*, 2022, in press. **impact factor: 3.508**.
123. B CELLS VERSUS T CELLS IN THE TUMOR MICROENVIRONMENT OF MALIGNANT LYMPHOMAS. ARE THE LYMPHOCYTES PLAYING THE ROLES OF MUHAMMAD ALI VERSUS GEROGGE FOREMAN IN ZAIRE 1974? Minodora Desmirean, Sebastian Rauch, Ancuta Jurj, Sergiu Pasca, Sabina Iluta, Patric Teodorescu, Cristian Berce, Andreea-Alina Zimta, Cristina Turcas, Irene Paris, Jakob Steinheber, Cedric Richlitzki, Bogdan Fetica, Delia Dima, Alina Tanase, Bobe Petrushev, **Ciprian Tomuleasa**. *Journal of Clinical Medicine*, 2020, in press. **impact factor: 35**.
124. EMERGENCY-DRIVEN MULTIPLE INVASIVE PROCEDURES IN HAEMOPHILIA. Cristina Emilia Ursu, Margit Serban, Jenel Marian Patrascu, Daniel Coriu, Jenel Marian Patrascu Jr, Ioana Ionita, Adina Traila, **Ciprian Tomuleasa**, Delia Savescu, Melen Brinza, Codrut Ivan, Teodora Smaranda Arghirescu. *Life* 2024, in press. **impact factor: 3.2**.
125. ROP-ET: A PROSPECTIVE PHASE III TRIAL INVESTIGATING THE EFFICACY AND SAFETY OF ROPEGINTERFERON ALFA-2B IN ESSENTIAL THROMBOCYTHEMIA PATIENTS WITH LIMITED TREATMENT OPTIONS. Jean-Jacques Kiladjian, Francisca Ferrer Marin, Haifa Kathrin Al-Ali, Alberto Alvarez Larran, Eloise Beggiato, Maria Bieniaszewska, Massimo Breccia, Veronika Buxhofer-Ausch, Olga Cerna, Ana-Manuela Crisan, Catalin Doru Danaila, Valerio De Stefano, Konstanze Doehner, Victoria Empson, Joanna Gora-Tybor, Martin Griesshammer, Sebastian Grosicki, Paola Guglielmelli, Jose Valentin Garcia Gutierrez, Florian Heidel, Arpád Illés, **Ionut-Ciprian Tomuleasa**, Chloe James, Steffen Koschmieder, Maria-Theresa Krauth, Kurt Krejcy, Mihaela-Cornelia Lazaroiu, Jiri Mayer, Zsolt György Nagy, Franck-Emmanuel Nicolini, Francesca Palandri, Vassiliki Pappa, Andreas Johannes Reiter, Tomasz Sacha, Stefanie Schlager, Stefan Schmidt, Evangelos Terpos, Martin Unger, Albert Woelfler, Blanca Xicoy Cirici, Christoph Klade. *Annals of Hematology* 2023, in press, **impact factor: 3.5**.

126. OUTCOMES OF HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR LYMPHOMA WITH MELPHALAN-BASED CONDITIONING. Jonathan E. Brammer, Issa Khouri, Sameh Gaballa, Paolo Anderlini, Sairah Ahmed, Celina Ledesma, **Ciprian Tomuleasa**, Chitra Hosang, Richard E. Champlin, Stefan O. Ciurea. *Biology of Blood and Marrow Transplantation* 2015, 2016; 22(3):493-8. **impact factor: 3.404.**
127. CUTANEOUS WOUND HEALING USING POLYMERIC SURGICAL DRESSINGS BASED ON CHITOSAN, SODIUM HYALURONATE AND RESVERATROL. Cristian Berce, Isabella Rigo, Bobe Petrushev, Lucia Tefas, Gheorghe Ungureanu, Mihai-Stefan Muresan, Olga Soritau, Cornel Catoi, Alexandru Irimie, **Ciprian Tomuleasa**. *Colloids and Surfaces B. Biointerfaces*, in press 2017. **impact factor: 3.387.**
128. CASTLEMAN'S DISEASE IN THE HIV-ENDEMIC SETTING. Esam-Rajab Mahroug, Candice Sher-Locketz, Minodora-Silvia Desmirean, Emmanuel-Akinola Abayomi, **Ciprian Tomuleasa**, Ravnit Grewal. *Cancer Management and Research*, 2018, in press. **impact factor: 3.351.**
129. SYSTEMIC SIDE-EFFECTS OF FDA AND/OR EMA-APPROVED TARGETED THERAPIES FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES. Catalin Constantinescu, Sergiu Pasca, Alina-Andreea Zimta, Tiberiu Tat, Ioana Rus, Patric Teodorescu, Sabina Iluta, Alina Tanase, Olafur Sigurjonsson, Hermann Einsele, **Ciprian Tomuleasa**. *Journal of Clinical Medicine*, 2020, in press. **impact factor: 3.303.**
130. OUTCOMES OF CAR T CELL THERAPY RECIPIENTS ADMITTED TO THE ICU: IN SEARCH FOR A STANDARD OF CARE – A BRIEF OVERVIEW AND METANALYSIS OF PROPORTIONS. Cătălin Constantinescu, Vlad Moisoiu, Bogdan Tigiu, David Keyes, Ciprian Tomuleasa. *Journal of Clinical Medicine* 2023, submitted for publication. **impact factor: 3.303.**
131. REAL-WORLD TREATMENT PATTERNS AND CLINICAL OUTCOMES IN PATIENTS WITH AML UNFIT FOR FIRST-LINE INTENSIVE CHEMOTHERAPY. Miyakawa Yoshitaka, Sanford David, Tomuleasa Ciprian, Hsiao Hui Hua, Enjeti Anoop, Gimenez Conca Alberto, Bernal del Castillo Teresa, Girshova Larisa, Martelli Maria, Guvenc Birol, Delgado Alexander, Duan Yinghui, Llamas Cynthia D, Lee Je-Hwan. *Leukemia and Lymphoma*, 2021, in press. **impact factor: 3.28.**
132. ANTIPROLIFERATIVE EFFECT OF NOVEL PLATINUM(II) AND PALLADIUM(II) COMPLEXES ON HEPATIC TUMOR STEM CELLS IN VITRO. Natalia Miklášova, Eva Fischer-Fodor, Peter Lönnecke, **Ciprian Ionut Tomuleasa**, Piroska Virag, Maria Perde-Schrepler, Roman Mikláš, Luminita Silaghi-Dumitrescu, Evamarie Hey-Hawkins. *European Journal of Medicinal Chemistry* 2012, 49C:41-47. **impact factor: 3.27**
133. SYNTHESIS AND *IN VITRO* ANTIPROLIFERATIVE ACTIVITY OF NEW THIAZOLO [4,5-B]PHENOTHIAZINE AGAINST HUMAN LEUKEMIA. Balasz Brem, Emese Gal, Luiza Gaina, Castelia Cristea, Luminita Silaghi-Dumitrescu, Eva Fischer-Fodor, **Ciprian Ionut Tomuleasa**, Adriana Grozav, Valentin Zaharia, Lorena Filip. *International Journal of Molecular Sciences*, in press. **impact factor 3.257.**
134. MESENCHYMAL STEM CELLS IN MYELOPROLIFERATIVE DISORDERS – FOCUS ON PRIMARY MYELOFIBROSIS. Sonia Selicean, **Ciprian Tomuleasa**,

- Ravnit Grewal, Graca Almeida-Porada, Ioana Berindan-Neagoe. Leukemia and Lymphoma, 2018, accepted for publication. **impact factor: 3.093.**
135. LABEL-FREE SERS ON BLOOD GENOMICS DNA. TOWARDS THE DETECTION OF ACUTE MYELOID LEUKEMIA IN PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION. Vlad Moisoiu, Andrei Stefancu, Stefania Iancu, Tudor Moisoiu, Luminita Loga, Lucia Dican, Cristian Alecsa, Imre Boros, Anca Jurj, Delia Dima, Cristina Bagacean, Romulus Tetean, Emil Burzo, **Ciprian Tomuleasa**, Florin Elec, Nicolae Leopold. Analytical and Bioanalytical Chemistry, 2019, in press. **impact factor: 3.307.**
136. MICRORNA-21 INHIBITS SERPINI 1, A GENE WITH NOVEL TUMOR SUPPRESSIVE EFFECTS IN GASTRIC CANCER. Sumitaka Yamanaka, Alexandru V Olaru, Delgermaa Luvsanjav, Fangmei An, Zhe Jin, Rachana Agarwal, **Ciprian Tomuleasa**, Irinel Popescu, Sorin Alexandrescu, Delia Dima, Mihaela Chivu-Economescu, Elizabeth A. Montgomery, Michael Torbenson, Christine Vazquez, Stephen J Meltzer, Florin M Selaru. Digestive and Liver Diseases, 2012, 44(7)589-596. **impact factor: 3.05**
137. CAPILLARY LEAK SYNDROME ASSOCIATED WITH ANAPLASTIC T CELL LYMPHOMA AND TRANSCUTANEOUS EXUDATION. Radu Tomai, Antonia Oancea, Ciprian Tomuleasa, Delia Dima. Diagnostics 2024, submitted for publication. **impact factor: 3.0.**
138. “LAZARUS RESPONSE” WHEN FETO-MATERNAL MICROCHIMERISM KICKS IN ... SPONTANEOUS REMISSION IN REFRACTORY PRIMARY MEDIASTINAL B CELL LYMPHOMA FOLLOWING TWIN PREGNANCY. Radu Tomai, Sabina Iluta, Adrian-Bogdan Tigu, Madalina Nistor, Anamaria Bancos, Diana Cenariu, Ciprian Jitaru, Sergiu Patcas, Delia Dima, David Kegyes, Sanda Buruiana, Mihnea Zdrengha, Alina Tanase, **Ciprian Tomuleasa**, Romeo Micu. Diagnostics 2024, in press. **impact factor: 3.0.**
139. Hsiao HH, Enciso Olivera LJ, Ito T, Bui C, Sanford D, Duan Y, Garbayo Guijarro MB, Martelli M, Bernal del Castillo T, Girshova L, Delgado A, Enjeti A, Tomuleasa C, Guvenc B, Llamas C, Lee JH, Gimenez Conca A. Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first-line systemic treatment or best supportive care: A multicenter international study. European Journal of Haematology 2022, in press. **impact factor: 2.997.**
140. LOW MOLECULAR WEIGHT HEPARINS (LMWH) AND SYNTHETIC FACTOR X INHIBITORS CAN IMPAR THE OSSEOINTEGRATION OF TITANIUM IMPLANT IN ANIMAL MODEL. Dragos Apostu, Bianca Berechet, Daniel Oltean-Dan, Alexandru Mester, Bobe Petrushev, Catalin Popa, Madalina Luciana Gherman, Adrian Bogdan Tigu, **Ciprian Ionut Tomuleasa**, Lucian Barbu-Tudoran, Horea Rares Ciprian Benea, Doina Piciu. Medicina 2022, in press. **impact factor: 2.94.**
141. THE NEW ERA OF NANOTECHNOLOGY, AN ALTERNATIVE TO CHANGE CANCER TREATMENT. Ancuta Jurj, Laura Pop, Cornelia Braicu, **Ciprian Tomuleasa**, Claudia Gherman, Ioana Berindan-Neagoe. Drug Design, Development and Therapy, in press. **impact factor: 2.881.**
142. MICRORNAS FOR THE DIAGNOSIS OF GRAFT VERSUS HOST DISEASE. **Ciprian Tomuleasa**, Shigeo Fuji, Andrei Cucuianu, Markus Kapp, Sonia Selicean, Alina

- Tanase, Delia Dima, Bobe Petrushev, Valentina Pileczki, Ioana Berindan-Neagoe, Alexandru Irimie, Hermann Einsele. *Annals of Hematology* 2015, 94(7):1081-92. **impact factor: 2.866.**
143. DESIGN OF FLT3 INHIBITOR GOLD NANOPARTICLE CONJUGATES AS POTENTIAL THERAPEUTIC AGENTS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA. Timea Simon, **Ciprian Tomuleasa**, Anca Bojan, Ioana Berindan-Neagoe, Sanda Boca, Simion Astilean. *Nanoscale Research Letters* 2015, 2015; 10(1):466. **impact factor: 2.78.**
144. CLINICOPATHOLOGICAL ANALYSIS OF A CASE SERIES OF PERIPHERAL T-CELL LYMPHOMAS, NOT OTHERWISE SPECIFIED, OF LYMPHOEPITELIOID VARIANT (LENNER'S LYMPHOMA). A CENTRAL EUROPEAN SINGLE-CENTER STUDY. Grigore-Aristide Gafencu, Sonia Selicean, Bobe Petrushev, Andrei Cucuianu, Delia Dima, Ioana Frinc, Alexandru Irimie, Rares Buiga, Valentina Pileczki, Ioana Berindan-Neagoe, Cristian Berce, **Ciprian Tomuleasa**. *Human Pathology*, 2016; 53:192-4. **impact factor: 2.769.**
145. INFLAMMATION, TUMORAL MARKERS AND INTERLEUKIN-17, -10 AND -6 PROFILES IN PANCREATIC ADENOCARCINOMA AND CHRONIC PANCREATITIS. Alina Tantau, Daniel-Corneliu Leucuta, Marcel Tantau, Emil Botan, Roxana Zaharie, **Ionut-Ciprian Tomuleasa**. *Digestive Diseases and Sciences*, 2020, in press. **impact factor: 2.751.**
146. LARGE INTRON INVERSIONS IN ROMANIAN PATIENTS WITH HEMOPHILIA A – FIRST REPORT. Melen Brinza, Andra Grigore, Mihaela Dragomir, Dumitru Jardan, Cerasela Jardan, Paul Balanescu, Claudia Cristina Tarniceriu, Oana Viola Badulescu, Cristina Blag, **Ciprian Tomuleasa**, Adina Traila, Margit Serban, Daniel Coriu. *Medicina* 2023, in press. **impact factor: 2.6.**
147. THE ROLE OF TGF- β IN TISSUE MICROENVIRONMENT: A POTENTIAL NEW THERAPEUTIC APPROACH IN HCC TREATMENT. Bhavna Rani, Yuan Cao, Andrea Malfettone, **Ciprian Tomuleasa**, Isabel Fabregat, Gianluigi Giannelli. *World Journal of Gastroenterology* 2014, 20(15):4128-4140. **impact factor: 2.547.**
148. REPOSITIONING METFORMIN IN CANCER: GENETICS, DRUG TARGETS AND NEW WAYS OF DELIVERY. Mihaela Aldea, Lucian Craciun, **Ciprian Tomuleasa**, Ioana Berindan-Neagoe, Gabriel Kacso, Ioan-Stefan Florian, Carmen Crivii. [Tumour Biology](#). 2014; 35(6):5101-10. **impact factor: 2.518.**
149. THE INFLUENCE OF METHYLATING MUTATIONS ON CHOOSING ACUTE MYELOID LEUKEMIA CHEMOTHERAPY. PRELIMINARY ANALYSIS ON 58 PATIENTS. Sergiu Pasca, Cristina Turcas, Ancuta Jurj, Patric Teodorescu, Sabina Iluta, Ionut Hotea, Cristina Selicean, Bogdan Fetica, Bobe Petrushev, Vlad Moisoiu, Alina-Andreea Zimta, Valentina Sas, Catalin Constantinescu, Mihnea Zdrenghea, Delia Dima, **Ciprian Tomuleasa**. *Diagnostics*, 2020, in press. **impact factor: 2.489.**
150. CLINICAL REMISSION FOR AN ELDERLY PATIENT WITH A MASSIVE PRIMARY CUTANEOUS PERIPHERAL T-CELL LYMPHOMA-NOS OF THE EYE, FOLLOWING COMBINATION CHEMOTHERAPY WITH ETOPOSIDE PLUS COP. Sabina Iluta, Dragos-Alexandru Termure, Bobe Petrushev, Mindra-Eugenia Badea, Madalina Moldovan-Lazar, Manuela Lenghel, Csaba Csutak, Andrei Roman, Sergiu

- Pasca, Cedric Richlitzki, Sebastian Rauch, Delia Dima, **Ciprian Tomuleasa**, Rares-Calin Roman. *Diagnostics*, 2020, in press. **impact factor: 2.489.**
151. GELATIN COATED GOLD NANOPARTICLES AS CARRIERS OF FLT3 INHIBITOR DRUGS FOR ACUTE MYELOID LEUKEMIA TREATMENT. Sorina Suarasan, Timea Simon, Sanda Boca, **Ciprian Tomuleasa**, Simion Astilean. *Chemical Biology and Drug Design*, 2016; 87(6):927-35. **impact factor: 2.485.**
152. USE OF FLOW CYTOMETRY IN THE PHENOTYPIC AND DIAGNOSIS OF HODGKIN'S LYMPHOMA. Ravnit Grewal, Manogari Chetty, Emmanuel Akinola Abayomi, **Ciprian Tomuleasa**, Jonathan R. Fromm. *Cytometry Part B. Clinical Cytometry*, 2018 in press. **impact factor: 2.474.**
153. PERIODONTAL DISEASE AND VON WILLEBRAND DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS. Alexandru Mester, Leonardo Mancini, Enrico Marchetti, Mihaela Baciut, Simion Bran, Ondine Lucaciu, Grigore Baciut, **Ciprian Tomuleasa**, Sergiu Pasca, Andra Piciu, Andrada Voina-Tonea, Horia Opris, Daiana Antoaneta Prodan, Florin Onișor. *Applied Sciences*, 2021, in press. **impact factor: 2.474.**
154. NOVEL PALADIUM (III) COMPLEXES INFLUENCE PROMININ-1/CD133 EXPRESSION AND STEM CELL FACTOR RELEASE IN TUMOR CELLS. Natalia Miklášova, Eva Fischer-Fodor, Roman Mikláš, Mihai Cenariu, Piroška Virag, **Ciprian I Tomuleasa**, Corina Tatomir, Ioana Berindan-Neagoe, Ferdinand Devínsky. *Molecules (Basel)*, 2017; 22(4). pii: E561. **impact factor 2.465.**
155. METFORMIN, ARSENIC TRIOXIDE, OLANZAPINE AND BETA-BLOCKERS AS NEW HORIZONS FOR GLIOBLASTOMA THERAPY. HAS TIME COME FOR CLINICAL TRIALS? Marco Carmignani, Mihaela Aldea, Olga Soritau, Anna Rita Volpe, Alexandru Irimie, Ioan-Stefan Florian, **Ciprian Tomuleasa**, Bobe Petrushev, Adriana Baritchii, Gianina Crisan, Guido Valle. *Journal of biological regulators and homeostatic agents* 2014, 28(1):1-15. **impact factor: 2.406.**
156. SEROPREVALENCE OF BARTONELLA SPECIES, COXIELLA BURNETII AND TOXOPLASMA GONDII AMONG PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: A PILOT STUDY IN ROMANIA. Chelsea J. Messinger, Eugen Gurzau, Ed Breitschwerdt, **Ciprian Tomuleasa**, Sally Trufan, Ricardo G. Maggi, Ioana Berindan-Neagoe, Peter Rabinowitz. *Zoonoses and Public Health* 2017, in press. **impact factor: 2.369.**
157. THE USE OF ROTATION TO FENTANYL IN CANCER-RELATED PAIN. Delia Dima, **Ciprian Tomuleasa**, Ioana Frinc, Sergiu Pasca, Lorand Magdo, Mihai Muresan, Ioana Berindan-Neagoe, Cosmin Lisencu, Alexandru Irimie, Mihnea Zdrenghia. *Journal of Pain Research*, 2017; 10:341-348. **impact factor: 2.363.**
158. JAK2 V617F ALLELE BURDEN CONTRIBUTED TO THE OCCURANCE OF MAJOR THROMBOSIS IN POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA. Adrian Trifa, Claudia Banescu, Cristian Voina, Stefana Popa, Tunde Torok-Vistai, Anca Bojan, Delia Dima, Mihnea Zdrenghia, Bogdan Fetica, Simona Visan, **Ciprian Tomuleasa**, Bogdan Pop, Viola Popov, Mihaela Andreescu, Radu Popp. *Blood Cells, Molecules and Disease* 2018, in press. **impact factor: 2.331.**
159. ADULT ACUTE MEGAKARYOBLASTIC LEUKEMIA. RARE ASSOCIATION WITH CYTOPENIAS OF UNDETERMINED SIGNIFICANCE AND P210 AND P190 *BCR-ABL* TRANSCRIPTS. Delia Dima, Liana Oprita, Ana-Maria

Rosu, Bobe Petrushev, Adrian Trifa, Cristina Selicean, Vlad Moisoiu, Ioana Rus, Mihnea Zdrengha, **Ciprian Tomuleasa**. OncoTargets and Therapy, in press. **impact factor: 2.311.**

160. BCR-ABL T315I MUTATION, A NEGATIVE PROGNOSTIC FACTOR FOR THE TERMINAL PHASE OF CHRONIC MYELOGENOUS LEUKEMIA TREATED WITH FIRST AND SECOND LINE TYROSINE KINASE INHIBITORS, MIGHT BE AN INDICATOR OF ALLOGENEIC STEM CELL TRANSPLANTATION AS THE TREATMENT OF CHOICE. **Ciprian Tomuleasa**, Delia Dima, Ioana Frinc, Mariana Patiu, Bobe Petrushev, Andrei Cucuianu, Ioana Berindan-Neagoe. Leukemia and Lymphoma 2015, 56(2):546-7. **impact factor: 2.301.**
161. BASIC KNOWLEDGE ON BCR-ABL1 POSITIVE EXTRACELLULAR VESICLES. Ancuta Jurj, Sergiu Pasca, Patric Teodorescu, **Ciprian Tomuleasa**, Ioana Berindan-Neagoe. Biomarkers in Medicine, 2020, in press, **impact factor: 2.268.**
162. IMPLICATION OF TET2 IN CAR-T CELL ACTIVITY AND TARGET'S RESPONSE TO CAR-T CELL THERAPY. LEASSONS LEARNED FROM T-CELLS. Sergiu Pasca, Ancuta Jurj, Catalin Constantinescu, Mihnea Zdrengha, **Ciprian Tomuleasa**. Critical Reviews in Immunology, 2021, in press. **impact factor: 2.237.**
163. THE LAUREN CLASSIFICATION HIGHLIGHTS THE ROLE OF EPITHELIAL-TO-MESENCHYMAL TRANSITION IN CARCINOGENESIS: AN IMMUNOHISTOCHEMISTRY STUDY OF THE STAT3 AND ADHESION MOLECULES EXPRESSION. Sergiu Susman, Raphaelle Barnoud, Frederique Bibeau, Francesco Borini, Marc Pocard, **Ciprian Tomuleasa**, Jean-Christophe Sabourin. Journal of Gastrointestinal and Liver Diseases 2015, 24(1):77-83. **impact factor: 2.202.**
164. DO LYMPHOMAS HAVE AN AUTOIMMUNE BACKGROUND AND HOW CAN WE INCREASE THE SENSITIVITY OF THE DIAGNOSIS OF PRIMARY PANCREATIC LYMPHOMA WITH RELATIVELY SAMLL SAMPLES ? Ciprian Tomuleasa, Emmanuel Akin-Abayomi, Delia Dima, Cristian Tefas, Alexandru Irimie, Bobe Petrushev, Ioana Frinc, Ravnit Grewal. Journal of Gastrointestinal and Liver Diseases 2015, 24(3):391-2. **impact factor: 2.202.**
165. EXOSOME-CARRIED MICRORNA-375 INHIBITS CANCER CELL PROGRESSION VIA BCL-2 BLOCKING IN COLON CANCER. Mihai-Stefan Muresan, Florin Zaharie, Bobe Petrushev, Cristian Berce, Grigore Gafencu, Sonia Selicean, Ancuta Jurj, Roxana Cojocneanu-Petric, Cosmin-Ioan Lisencu, Laura-Ancuta Pop, Valentina Pileczki, Dan Eniu, Mihai-Andrei Muresan, Roxana Zaharie, Ioana Berindan-Neagoe, **Ciprian Tomuleasa**, Alexandru Irimie. Journal of Gastrointestinal and Liver Diseases 2015, 2015; 24(4):435-43. **impact factor: 2.202.**
166. HENOCH SCHONLEIN PURPURA AND CLOSTRIDIUM DIFFICILE INFECTION, A HEMATOLOGISTS' POINT OF VIEW. Delia Dima, **Ciprian Tomuleasa**, Mihnea Zdrengha. Journal of Gastrointestinal and Liver Diseases, 2016; 25(3):411.. **impact factor: 2.202.**
167. HOW TO DIAGNOSE AND TREAT A CANCER OF UNKNOWN PRIMARY SITE. **Ciprian Tomuleasa**, Mihai Stefan Muresan, Florin Zaharie, Laura Pop, Zsolt Fekete, Delia Dima, Ioana Frinc, Adrian Trifa, Cristian Berce, Ancuta Jurj, Ioana Berindan-Neagoe, Mihnea Zdrengha, Tudor Ciuleanu. Journal of Gastrointestinal and Liver Diseases, 2017; 26(1):69-79. **impact factor: 2.202.**

168. ANTIPROLIFERATIVE AND APOPTOTIC IN VITRO EFFECTS OF LIDOCAINE ON HUMAN HEPATOCARCINOMA CELLS. Ancuta Jurj, **Ciprian Tomuleasa**, Tiberiu Tat, Ioana Berindan-Neagoe, Stefan V. Vesa, Daniela Ionescu. Journal of Gastrointestinal and Liver Diseases, 2017; 26(1):45-50. **impact factor: 2.202.**
169. NEXT GENERATION SEQUENCING-BASED CHARACTERIZATION OF THE INVASION BY ANATOMICAL CONTIGUITY IN A PRIMARY OSSEOUS DIFFUSE LARGE B-CELL LYMPHOMA. Florin Zaharie, Laura-Ancuta Pop, Bobe Petrushev, Mihai-Stefan Muresan, Dan Eniu, Bogdan Fetica, Doina Piciu, Ioana Rus, Delia Dima, **Ciprian Tomuleasa**, Ioana Berindan-Neagoe. Histology and Histopathology, 2018, in press. **impact factor: 2.025.**
170. MANAGEMENT OF RENAL EXTRASKELETAL CHONDROSARCOMA. Vitalie Gherman, **Ciprian Tomuleasa**, Catalina Bungardean, Dan Vasile Stanca, Victor Dan Ona, Bogdan Feciche, Alexandru Irimie, Ioan Coman. BMC Surgery 2014, 2014; 14:107. **impact factor: 1.97.**
171. CHRONIC GRANULAMATOUS DERMATOSIS AS A PRESENTING SIGN FOR CUTANEOUS T-CELL LYMPHOMAS. Andrei Cucuianu, Bobe Petrushev, Doinita Crisan, Rares Buiga, Ana Maria Rosu, Delia Dima, **Ciprian Tomuleasa**. European Journal of Dermatology 2015, 25(2):210. **impact factor: 1.92.**
172. GOLD NANOPARTICLES CONJUGATED WITH CISPLATIN/ DOXORUBICINE/ CAPECITABINE LOWER THE CHEMORESISTANCE OF HEPATOCELLULAR CARCINOMA-DERIVED CANCER CELLS. **Ciprian Tomuleasa**, Olga Sorit au, Anamaria Orza, Mircea Ducea, Bobe Petrushev, Ofelia Mosteanu, Sergiu Susman, Adrian Florea, Eموke Pall, Mihaela Aldea, Gabriel Kacso, Victor Cristea, Ioana Berindan-Neagoe, Alexandru Irimie. Journal of Gastrointestinal and Liver Diseases 2012, 21(2):187-196. **impact factor: 1.81**
173. ISOLATION AND CHARACTERIZATION OF HEPATIC CANCER CELLS WITH STEM LIKE PROPERTIES FROM HEPATOCELLULAR CARCINOMA, **Ciprian Tomuleasa**, Olga Sorit au, Dan Rus Ciuc a, Teodora Pop, Daniela Todea, Ofelia Moşteanu, Bogdan Pinteau, Vasile Foris, Sergiu Suşman, Gabriel Kacs o, Alexandru Irimie, Journal of Gastrointestinal and Liver Diseases, 2010; 19(1):61-67. **impact factor: 1.81**
174. ALDH AS A TUMOR MARKER FOR PANCREATIC CANCER. **Ciprian Tomuleasa**, Ofelia Mosteanu, Sergiu Susman, Victor Cristea. Journal of Gastrointestinal and Liver Diseases 2011, 20(4):443-446. **impact factor: 1.81**
175. PARASITAEMIA AND HEMATOLOGICAL ALTERATIONS IN MALARIA-AFFECTED REFUGEES IN SOUTH AFRICA. Nonzwakazi Pretty Ntombela, Joyce Mahlako Tsoka-Gwegweni, Uchenna Okafor, Andrei Bibirigea, Alexandru Irimie, **Ciprian Tomuleasa**. South African Medical Journal, 2015, in press. **impact factor: 1.712**
176. COMPARISON OF PERIPHERAL BLOOD STEM CELL MOBILIZATION WITH FILGRATIM VERSUS PEGFILGRASTIM IN LYMPHOMA PATIENTS – SINGLE CENTER EXPERIENCE. Lavinia Lipan, Andrei Colita, Laura Stefan, Carmen Calugaroiu, Catalin Serban, **Ciprian Tomuleasa**, Sergiu Pasca, Anca Colita, Alina Tanase. Journal of the Balkan Union of Oncology 2021; 26(3): 1080-1087. **impact factor: 1.695.**

177. PROSPECTIVE INVESTIGATION OF PAIN ASSOCIATED WITH ULTRASOUND AND COMPUTED TOMOGRAPHY-GUIDED PERCUTANEOUS BIOPSIES IN ONCOLOGICAL PATIENTS. Andrei Roman, Federica Palego, Patriciu Achimas-Cadariu, Catalin Vlad, Alexandra Andries, **Ciprian Tomuleasa**, Vlad Alexandru Gata, Roxana Pintican, Patricia Maria Rada, Diana Feier. Medical Ultrasonography, 2020, in press. **impact factor: 1.674.**
178. SORAFENIB FOR ADVANCED STAGE HEPATOCELLULAR CARCINOMA. **Ciprian Tomuleasa**, Victor Cristea, Alexandru Irimie. European Journal of Gastroenterology and Hepatology, 2012, 24(3):346-347. **impact factor: 1.66**
179. BASELINE CHARACTERISTICS OF A NATIONWIDE COHORT OF PEDIATRIC PATIENTS WITH ACUTE LEUKEMIAS OF DOWN SYNDROME. Valentina Sas, Cristina Blag, Sergiu Pasca, Gheorghe Popa, Mirela Marian, Cristina Schnell, Daniela Voda, Smaranda-Teodora Arghirescu, Patric Teodorescu, Sabina Iluta, Cristina Turcas, Cristina Selicean, Anca Bojan, Mihnea Zdrenghea, Margit Serban, Delia Dima, Gabriela Zaharie, Anca Colita, Sorin Man, **Ciprian Tomuleasa**. Journal of the Balkan Union of Oncology, 2020, in press, **impact factor: 1.6.**
180. RISK FACTORS AND OUTCOMES OF ANAEMIA AND BLOOD TRANSFUSIONS IN PLASTIC SURGERY PATIENTS. Ioana Tichil, Teodora Tichil, Ioan Stefan Haplea, **Ciprian Tomuleasa**, Lucian Fodor, Ileana Mitre. Journal of International Medical Research 2024, in press. **impact factor: 1.6.**
181. MATRIX-METALLOPROTEINASE-2 PREDICTS ARTERIOVENOUS FISTULA FAILURE IN HAEMODIALYSIS PATIENTS. Dacian Tirinescu, **Ciprian Tomuleasa**, Laura Pop, Dan Vladutiu, Crina Rusu, Dana Moldovan, Alina Potra, Ina Kacso. Therapeutic Apheresis and Dialysis, 2017, in press, **impact factor: 1.529.**
182. TOPICAL CORTICOSTEROIDS, A VIABLE SOLUTION FOR ORAL GRAFT VERSUS HOST DISEASE? A SYSTEMATIC INSIGHT ON RANDOMIZED CLINICAL TRIALS. Arin Sava, Andra Piciu, Sergiu Pasca, Alexandru Mester, **Ciprian Tomuleasa**. Medicina (Kaunas), 2020, in press. **impact factor: 1.5.**
183. SILTUXIMAB IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE: REAL WORLD EXPERIENCE FROM GREECE AND ROMANIA. Ciprian Jitaru, Argyris Symeonidis, Sorina Badelita, Eirini Katodritou, Andrei Colita, Anastasia Mpanti, Anamaria Bancos, Bogdan Tigiu, Petra Rotariu, Vasiliki Labropoulou, Mihai Stefan Muresan, Despina Fotiou, Bogdan Fetica, Bobe Petrushev, Delia Dima, Angela Dascalescu, Laura Urian, Dimitra Dalampira, Catalin Constantinescu, Mihnea Zdrenghea, Meletios A. Dimopoulos, **Ciprian Tomuleasa**, Evangelos Terpos. Journal of Hematology 2024, **impact factor: 1.5**, in press
184. DNMT3A R882 AND TET2/IDH1/2 MUTATIONS IMPACT BLAST CELL DIFFERENTIATION IN ACUTE MYELOID LEUKEMIA BUT NOT RESPONSE TO HYPOMETHYLATING AGENTS. Sergiu Pasca, Ancuta Jurj, **Ciprian Tomuleasa**, Mihnea Zdrenghea, Medicina, **impact factor: 1.2.** in press, 2020.
185. GOLD NANOPARTICLES CONJUGATED WITH RITUXIMAB FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA. Sanda Boca, Ciprian Lucan, Ioana Frinc, Bobe Petrushev, Timea Simon, Cristian Berce, Grigore-Aristide Gafencu, Delia Dima, Alina Tanase, Sonia Selicean, Valentina Pileczki, Laura Pop, Adrian Florea, Alexandru Irimie, Simion Astilean, Anca Bojan, Ioana Berindan-Neagoe, Mihnea Zdrenghea, **Ciprian Tomuleasa**. Farmacia 2016, in pres **impact factor: 1.162.**

186. TRANSTHORACIC ULTRASONOGRAPHY FOR THE FOLLOW-UP OF A CHRONIC LYMPHOCYTIC LEUKEMIA CHEMOTHERAPY-IMMUNOCOMPROMISED PATIENT PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION. CASE REPORT. Ioana Frinc, Delia Dima, Mariana Chitic, Cristian Berce, Ioana Berindan-Neagoe, Tiberiu Tat, Alina Tanase, **Ciprian Tomuleasa**, Anca Bojan. Medical Ultrasonography, in press. **impact factor 1.167.**
187. A SYSTEMATIC APPROACH ON THE FREQUENCY OF LEFT LIP/PALATE IN PEDIATRIC PATIENTS WITH LEUKEMIA. Daiana Antoaneta Prodan, Simion Bran, Cristian Dinu, Grigore Baciut, **Ciprian Tomuleasa**, Andra Piciu, Alexandru Mester, Mihaela Baciut. Journal of Stomatology, Oral and Maxillofacial Surgery 2020, in press. **impact factor: 1.152.**
188. PARP INHIBITORS IN ACUTE MYELOID LEUKEMIA THERAPY: HOW A SYNTHETIC LETHALITY APPROACH CAN BE A VALID THERAPEUTIC ALTERNATIVE. Grigore Gafencu, **Ciprian Tomuleasa**, Gabriel Ghiaur. Medical Hypotheses, in press, **impact factor :1.136.**
189. REDISTRIBUTION OF IRON TOWARDS DEPOSITS IN ERYTHROBLASTOPENIC ANEMIA AS A CONSEQUENCE OF DECREASED ERYTHROFERRONE PRODUCTION. Andrei Cucuianu, Mariana Patiu, Adrian P. Trifa, **Ciprian Tomuleasa**, Delia Dima. Medical Hypotheses 2014, 83(5):530-2. **impact factor: 1.054.**
190. RUXOLITINIB CONJUGATED WITH GOLD NANOPARTICLES, USED FOR TOPICAL ADMINISTRATION. AN ALTERNATIVE FOR TREATING ALOPECIA ? Sanda Boca-Farcu, Cristian Berce, Bobe Petrushev, Ancuta Jurj, Laura Pop, Grigore-Aristide Gafencu, Sonia Selicean, Vlad Moisoiu, Daiana Temian, Wilhelm-Thomas Micu, Simion Astilean, Cornelia Braicu, **Ciprian Tomuleasa**, Ioana Berindan-Neagoe. Medical Hypotheses, in press. **impact factor: 1.03.**
191. HAPLOIDENTICAL DONORS: CAN FASTER TRANSPLANTATION BE LIFE-SAVING FOR PATIENTS WITH ADVANCED DISEASE ? Alina Tanase, **Ciprian Tomuleasa**, Alexandra Marculescu, Alexandru Bardas, Anca Colita, Carmen Orban, Stefan Octavian Ciurea. Acta Haematologica 2015, 2016;135(4):211-6.. **impact factor: 0.994**
192. THE IMPORTANCE OF MICRO-RNAS IN THE STROMAL-BREAST CANCER CELL INTERPLAY. Sergiu Susman, **Ciprian Tomuleasa**, Zsolt Fekete, Brunella Pilato, Alexandru Irimie, Ioana Berindan-Neagoe. [Cancer Biomarkers](#). 2014;14(2-3):137-44. **impact factor: 0.972**
193. HEMATOLOGY PATIENTS INFECTED WITH SARS-CoV-2 VIRUS, PRE-TREATED WITH ECULIZUMAB OR SILTUXIMAB, DEVELOP OLIGOSYMPTOMATIC DISEASE. Sabina Iluta, Sergiu Pasca, Delia Dima, Gabriela Mester, Laura Urian, Anca Bojan, Mihnea Zdrenghea, Adrian Trifa, Ovidiu Balacescu, **Ciprian Tomuleasa**. European Journal of Hospital Pharmacy, 2021, in press. **impact factor: 0.892.**
194. PARANEOPLASTIC SYNDROMES WITH CONNECTIVE TISSUE INVOLVEMENT. IT'S NOT ALWAYS LUPUS ! T Timis, C Berce, A Duarte-Garcia, B Petrushev, V Cristea, **C Tomuleasa**. Journal of the Balkan Union of Oncology 2012, 17:417-421. **impact factor: 0.76**

195. MESENCHYMAL STEM CELL IRRADIATION IN CULTURE ENGAGES DIFFERENTIAL EFFECT OF HYPERFRACTIONATED RADIOTHERAPY FOR HEAD AND NECK CANCERS, **C Tomuleasa**, V Foris, O Sorițau, T Dicu, E Páll, I Brie, G Kacsó, Journal of Balkanic Union of Oncology, 2010; 15(2):348-356. **impact factor: 0.76.**
196. FUNCTIONAL AND MOLECULAR CHARACTERIZATION OF GLIOBLASTOMA MULTIFORME DERIVED CANCER STEM CELLS, **C Tomuleasa**, O Sorițau, D Rus Ciucă, H Ioani, S Sușman, M Petrescu, T Timis, D Cernea, G Kacsó, A Irimie, IS Florian, Journal of Balkan Union of Oncology, 2010; 15(3):583-591. **impact factor: 0.76**
197. METFORMIN PLUS TEMOZOLOMIDE-BASED CHEMOTHERAPY AS ADJUVANT TREATMENT FOR WHO GRADE III AND IV MALIGNANT GLIOMAS. O Soritau, **C Tomuleasa**, M Aldea, B Petrushev, S Susman, D Gheban, H Ioani, A Cocis, A Irimie, G Kacso, IS Florian. Journal of the Balkan Union of Oncology, 2011, 16:282-289. **impact factor: 0.76**
198. ANTIDIABETIC PHARMACOLOGY, A LINK BETWEEN METABOLIC SYNDROME AND NEURO-ONCOLOGY? M Aldea, **C Tomuleasa**, B Petrushev, S Susman, G Kacso, A Irimie, IS Florian, O Soritau. Journal of the Balkan Union of Oncology, 2011, 16:409-413. **impact factor: 0.76**
199. CANCER STEM CELLS AND MALIGNANT GLIOMAS. FROM PATHOPHYSIOLOGY TO TARGETED MOLECULAR THERAPY, IS Florian, **C Tomuleasa**, O Soritau, T Timis, G Kacso, A Irimie. Journal of the Balkan Union of Oncology, 2011, 16:16-23. **impact factor: 0.76**
200. ARSENIC TRIOXIDE SENSITIZES CANCER STEM CELLS TO CHEMORADIOTHERAPY – A NEW APPROACH IN THE TREATMENT OF INOPERABLE GLIOBLASTOMA MULTIFORME, **C Tomuleasa**, O Soritau, G Kacso, E Fischer-Fodor, A Cocis, H Ioani, M Petrescu, T Timis, D Cernea, P Virag, A Irimie, IS Florian, Journal of the Balkan Union of Oncology, 2010, 15:758-762. **impact factor: 0.76**
201. THE COLORECTAL CANCER STEM-LIKE CELL HYPOTHESIS. A PATHOLOGIST'S POINT OF VIEW. S Susman, **C Tomuleasa**, O Soritau, D Rus-Ciucă, J-C Sabourin, F Bibeau, A Irimie, R Buiga. Journal of the Balkan Union of Oncology, 2012, 17(2):230-236. **impact factor: 0.76**
202. THE ROLE OF DEPRESSION AND NEUROIMMUNE AXIS IN THE PROGNOSIS OF CANCER PATIENTS. Mihaela Aldea, Lucian Craciun, **Ciprian Tomuleasa**, Carmen Crivii. Journal of the Balkan Union of Oncology 2014, 19(1):5-14. **impact factor: 0.76**
203. THE ANDROGEN RECEPTOR AS KEY PLAYER IN METASTATIC HORMONE-REFRACTORY PROSTATE CANCERS. IMPLICATIONS FOR NEW TREATMENTS. Adina Nemes, **Ciprian Tomuleasa**, Gabriel Kacsó. Journal of the Balkan Union of Oncology 2014, 19(2): 357-364. **impact factor: 0.76**
204. MICRORNA-21 STIMULATES GASTRIC CANCER GROWTH AND INVASION BY INHIBITING THE TUMOR SUPPRESSOR EFFECTS OF PROGRAMMED CELL DEATH PROTEIN 4 AND PHOSPHATASE AND TENSIN HOMOLOG. Ling Li, Liya Zhou, Yuwen Li, Sanren Lin, **Ciprian Tomuleasa**. Journal of the Balkan Union of Oncology 2014, 19(1):228-236. **impact factor: 0.76.**

205. CANCER STEM –LIKE CELLS: THE DARK KNIGHTS OF CLINICAL HEMATOLOGY AND ONCOLOGY. Ioana Frinc, Mihai-Stefan Muresan, Florin Zaharie, Ljubomir Petrov, Cristian Berce, Alexandra Irimie, Ioana Berindan-Neagoe, **Ciprian Tomuleasa**. Journal of the Balkan Union of Oncology 2014, 19(2): 328-335. **impact factor: 0.76.**
206. METFORMIN PLUS SORAFENIB - AN ASSOCIATION THAT HIGHLY IMPACTS TEMOZOLOMIDE-REZISTANT GLIOBLASTOMA STEM-LIKE CELLS. Mihaela Aldea, Bobe Petrushev, Olga Soritau, **Ciprian Tomuleasa**, Ioana Berindan-Neagoe, Adriana Filip, Gabriela Chereches, Mihai Cenariu, Lucian Craciun, Corina Tatomir, Ioan-Stefan Florian, Carmen Crivii, Gabriel Kacso. Journal of the Balkan Union of Oncology 2014, 19(2): 502-511. **impact factor: 0.76.**
207. THE EFFECT OF ANAESTHETIC ON NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN (NGAL) LEVELS AFTER ROBOTIC SURGICAL ONCOLOGY. Orsolya Mihály, Attila-Zoltan Mihály, Vitalie Gherman, Florin Zaharie, Sorana Bolboacă, Ciprian Chira, Constantin Bodolea, **Ciprian Tomuleasa**, Alexandru Irimie, Ioan Coman, Daniela Ionescu. Journal of the Balkan Union of Oncology 2015, 20(1):317-24. **impact factor: 0.76.**
208. MICRORNAS IN LIVER MALIGNANCIES. BASIC SCIENCE APPLIED IN SURGERY. Mihai-Stefan Muresan, Florin Zaharie, Anca Bojan, Bobe Petrushev, Roxana Cojocneanu-Petric, Alexandru Irimie, Grigore Gafencu, Sonia Selicean, Cristian Tefas, Andreea Cioca, Cristian Berce, Ioana Berindan-Neagoe, **Ciprian Tomuleasa**, Patriciu Achimas-Cadariu. Journal of the Balkan Union of Oncology 2015, 20(2):361-75. **impact factor: 0.76.**
209. ORAL SURGERY FOR COMBINED HAEMOPHILIA A AND B. THE DOS AND DON'TS IN A CLINICAL SCENARIO. Madalina Anca Lazar, Ovidiu Muresan, Calin Rares Roman, Delia Dima, Mihai Stefan Muresan, Gabriel Armencea, **Ciprian Tomuleasa**, Horatiu Rotaru. Ann Ital Chir, 2018; in press, **impact factor: 0.2.**
210. LAPAROSCOPIC SPLENECTOMY FOR HEREDITARY SPHEROCYTOSIS. Florin Zaharie, Mihai-Stefan Muresan, Cristina Blag, Roxana Zaharie, Claudiu Zdrehus, Mihnea Dragomir, Mihnea Zdrenghea, Horia Bumbea, Alexandru Irimie, Delia Dima, **Ciprian Tomuleasa**, Gheorghe Popa. Ann Ital Chir, submitted for publication. **impact factor: 0.2.**
211. EFFECTS OF Co GAMMA-RAYS ON HUMAN OSTEOPROGENITOR CELLS, **C.I. Tomuleasa**, V. Foris, Olga Sorițău, Emöke Páll, Eva Fischer-Fodor, V. Lung-Illes, Ioana Brie, Piroška Virág, Maria Perder-Schrepler, I.D. Postescu, Gabriela Cherecheș, Otilia Barbos, Corina Tatomir, Romanian Journal of Morphology and Embryology, 2009; 50(3):3-6.
212. PRIMUM NON NOCERE. IS STEM CELL RESEARCH READY FOR CLINICAL TRIALS ?, **Ciprian Tomuleasa**, Olga Sorițău, Sergiu Șuşman, Vasile Foris, Emöke Páll, Carmen Mihiu, Journal of the European Medical Students Association, 2009; 4(4):33-38.
213. ARSENIC TRIOXIDE PLUS CISPLATIN/ INTERFERON α -2B/ DOXORUBICIN/ CAPECITABINE COMBINATION CHEMOTHERAPY FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA, **Ciprian Tomuleasa**, Olga Sorițău, Teodora Pop, Eva Fischer-Fodor, Ofelia Mosteanu, Bobe Petrushev, Sergiu

- Susman, Mihaela Aldea, Monica Acalovschi, Alexandru Irimie, Gabriel Kacsó. Hematology Oncology and Stem Cell Therapy, 2011, 4(2):60-66.
214. ENHANCED CHEMORESISTANCE AND TUMOUR SPHERE FORMATION AS A LABORATORY MODEL FOR PERITONEAL MICROMETASTASIS IN EPITHELIAL OVARIAN CANCER, Olga Sorițău, **CI Tomuleasa**, Emöke Páll, Piroska Virág, Eva Fischer-Fodor, Gabriela Cherecheș, Otilia Barbos, Corina Tatomir, G Kacsó, A Irimie, Romanian Journal of Morphology and Embryology, 2010, 51(2):3-6.
215. CELLULAR INTERACTIONS IN PROSTATE CANCER GENESIS AND DISSEMINATION. LOOKING BEYOND THE OBVIOUS, **C Tomuleasa**, G Kacsó, S Șuşman, Olga Sorițău, Carmen Mihiu, A Irimie, Piroska Virág, Romanian Journal of Morphology and Embryology, 2010, 51(3):427-435.
216. PARANEOPLASTIC SYNDROMES AS KEY ELEMENTS OF DIFFERENTIAL DIAGNOSIS. Tanase Timis, Doru Tomesc, Bobe Petrushev, Claudiu Sas, Mihaela Aldea, **Ciprian Tomuleasa**. Journal of the European Medical Students Association, 2011, 6(1):7-12.
217. PLACENTAL STEM CELL DIFFERENTIATION INTO ISLETS OF LANGERHANS-LIKE GLUCAGON SECRETING CELLS. S Susman, Olga Soritau, D Rus-Ciuca, **C Tomuleasa**, VI Pop, Carmen Mihaela Mihiu. Romanian Journal of Morphology and Embryology, 2010, 51(4):733-738.
218. PANCREATIC EXOCRINE ADULT CELLS AND PLACENTAL STEM CELLS CO-CULTURE. WORKING TOGETHER IS ALWAYS THE BEST WAY TO GO. S Susman, Olga Soritau, D Rus-Ciuca, **C Tomuleasa**, R Buiga, D Mihiu, VI Pop, Carmen Mihaela Mihiu. Romanian Journal of Morphology and Embryology, 2011, 52(3 Suppl):999-1004.
219. METFORMIN PLUS PIAF COMBINATION CHEMOTHERAPY FOR HEPATOCELLULAR CARCINOMA. B. Petrushev, **C. Tomuleasa**, O. Soritau, M. Aldea, T. Pop, S. Susman, G. Kacso, I. Berindan-Neagoe, A. Irimie, V. Cristea. Experimental Oncology, 2012, 34(1):17-24.
220. ESTABLISHMENT OF AN EMBRYONIC STEM CELL LINE FROM BLASTOCYST STAGE MOUSE EMBRYOS. Evoke Pall, I Groza, M Cenariu, Olga Soritau, Elen Gocza, **C Tomuleasa**. Romanian Journal of Morphology and Embryology, 2011, 52(3 Suppl):1005-1010.
221. MINIMALLY INVASIVE ENUCLEATION WITH ZERO ISCHEMIA FOR MALIGNANCIES. THE CLUJ NAPOCA EXPERIENCE. Gherman V, **Tomuleasa C**, Irimie A, Coman I. American Journal of Case Reports 2013;14:511-2.
222. BICYTOPENIA AS A PARANEOPLASTIC SYNDROME FOR PSEUDOMYXOMA PERITONEI. HEMATOLOGIC MANIFESTATIONS OF A SUBTLE DISEASE. **Ciprian Tomuleasa**, Bobe Petrushev, Madalina Vedean, Alexandru Irimie, Florin Zaharie, Ana Maria Rosu, Delia Dima, Andrei Cucuianu, Ioana Frinc. International Journal of General Medicine 2015, 8:93-5.
223. FIRST SUCCESSFUL HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN ROMANIA. Alina Tanase, **Ciprian Tomuleasa**, Alexandra Marculescu, Alexandru Bardas, Anca Colita, Carmen Orban, Stefan Octavian Ciurea. Romanian Journal of Internal Medicine 2016, 2016 Sep 1;54(3):194-200.
224. PROCEEDINGS FROM THE 1ST INSIGHTS IN HEMATOLOGY SYMPOSIUM, CLUJ NAPOCA, ROMANIA MARCH 11-12, 2016. Anca Bojan, Ioana

- Berindan-Neagoe, Stefan Ciurea, Delia Dima, Shigeo Fuji, Gabriel Ghiaur, Ravnit Grewal, Emmet McCormack, Alina Tanase, Adrian Trifa, Ciprian Tomuleasa. Romanian Journal of Internal Medicine 2016 Sep 1;54(3):157-160.
225. TRANSTHORACIC ULTRASONOGRAPHY FOR THE IMMUNOCOMPROMISED PATIENT. Ioana Frinc, Petru Ilies, Delia Dima, Alina Tanase, Ljubomir Petrov, Alexandru Irimie, Bobe Petrushev, Cristian Berce, Mihai-Stefan Muresan, Cosmin Lisencu, Ioana Berindan-Neagoe, Anca Bojan, **Ciprian Tomuleasa**. Romanian Journal of Internal Medicine, 2016, in press.
226. ADVANCES IN THE TREATMENT OF NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMAS. Liren Qian, **Ciprian Tomuleasa**, Ioan-Alexandru Florian, Gheorghe Ungureanu, Ioan-Stefan Florian, Mihnea Zdrenghia, Jianliang Shen, Delia Dima. Blood Res 2017; 52(3): 159-166
227. HYPEREOSINIPHILIA IN A PATIENT WITH PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED. Minodora Desmirean, Dalma Deak, Ioana Rus, Delia Dima, Sabina Iluta, Alexandra Preda, Tiberiu Moldovan, Andrei Roman, **Ciprian Tomuleasa**, Bobe Petrushev. Medicine and Pharmacy Reports, 2019, in press.
228. CORRELATION BETWEEN PREVALENCE OF T-CELL LYMPHOMAS AND ALCOHOL CONSUMPTION. Minodora Desmirean, Cedric Richlitzki, Sergiu Pasca, Patric Teodorescu, Sebastian Rauch, Jacob Steinheber, Sabina Iluta, Jiaxin Liu, Delia Dima, Ravnit Grewal, Weina Ma, Liren Qian, **Ciprian Tomuleasa**, Bobe Petrushev. Medicine and Pharmacy Reports, 2021, in press.
229. COEXISTENCE OF TRISOMY 8 AND 13 IN A NEWLY DIAGNOSED PATIENT WITH DIFFUSE LARGE B CELL NON-HODGKIN LYMPHOMA AND ACUTE MYELOID LEUKEMIA SECONDARY TO PRIMARY MYELOFIBOSIS. [Horia Bumbea](#), [Viola Maria Popov](#), [Ciprian Tomuleasa](#), [Meilin Omer](#), [Camelia Dobrea](#), [Irina Manea](#), [Sabina Zurac](#), [Cristiana Popp](#), [Ion Dumitru](#), [Madalina Simoiu](#), [Bogdan Mastalier](#). Cureus 2022; 14(2): e22217.
230. EPYSQLI (SB12 ; BIOSIMILAR TO REFERENCE ECULIZUMAB) IN ASIAN AND NON-ASIAN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA : SUBGROUP ANALYSIS OF A GLOBAL PHASE III RANDOMIZED CONTROLLED TRIAL. Jun Ho Jang, **Ciprian Tomuleasa**, Hanna Oliynyk, Theerin Lanamtieng, Jihye Park, Younsoo Kim, Jinah Jung, Paola Russo, Junichi Nishumura, Soo Min Lim, Régis Peffault de Latour. eJHaem 2025, in press.

Aricole in curs de revizie (Peer review):

A MATHEMATICAL MODEL OF CLONAL HEMATOPIESIS EXPLAINING PHASE TRANSITIONS IN MYELOID LEUKEMIA. Lorand Gabriel Parajdi, Xue Bai, David Kegyes, **Ciprian Tomuleasa**. Mathematical Medicine and Biology 2024, submitted for publication.
impact factor: 1.1.

THE EFFECT OF CATIONS AND DNA METHYLATION ON THE ABSORPTION OF DNA ON SILVER NANOPARTICLES. Stefania D. Iancu, Vlad Moisoiu, Bogdan A. Tigau, Andrei

Stefancu, Oana M. Biro, **Ciprian Tomuleasa**, Nicolae Leopold. PloS One 2025, submitted for publication. **impact factor : 2.9**.

COMPREHENSIVE VIEW ON CHEMOTHERAPY-FREE MANAGEMENT OF LEUKEMIA BY USING VENETOCLAX IN COMBINATION WITH TARGETED AND/OR IMMUNE THERAPIES. David Keyes, Andrei Tat, Alin Stefan Vizitiu, Daiana Vazar-Tripon, Radu Ilie, Adrian Bogdan Tigiu, Diana Cenariu, Anamaria Bancos, Sabina Iluta, Ciprian Jitaru, Madalina Nistor, Radu Tomai, Hermann Einsele, Gabriel Ghiaur, Carlo M. Croce, **Ciprian Tomuleasa**. Cell Death Discovery 2025, submitted for publication. **impact factor: 6.1**.

CHALLENGES IN THE PRECLINICAL DESIGN AND ASSESSMENT OF CAR T CELLS. Radu Tomai, Klaudyna Fidy, Rui Bergatim, Brankica Filipic, Zarko Gagic, Katarina Nikolic, Diana Gulei, David Keyes, Madalina Nistor, Ximena Maria Muresan, Diana Cenariu, Richard Feder, Adrian Bogdan Tigiu, Raluca Munteanu, Alina Tanase, Hermann Einsele, **Ciprian Tomuleasa**. Frontiers in Immunology 2025, submitted for publication, **impact factor : 5.7**.

REAL LIFE EXPERIENCE WITH AN EASTERN EUROPEAN COHORT OF PATIENTS WITH ACUTE HEPATIC PORPHYRIA TREATED WITH RNA INTERFERENCE-BASED GIVOSIRAN. Anamaria Bancos, Ciprian Jitaru, Andrada Uhl, Diana Roibu, Adrian-Bogdan Tigiu, Diana Cenariu, Madalina Nistor, Raluca Munteanu, Maria Santa, Anca Bojan, Mihnea Zdrengea, Diana Gulei, Delia Dima, **Ciprian Tomuleasa**. Hepatology International 2025, **impact factor : 5.9**, submitted for publication

HUMANIZED MOUSE MODELS IN MDS. Raluca Munteanu, Diana Gulei, Cristian-Silviu Moldovan, Emanuele Azzoni, Laura Belver, Richard Feder, Simina Pirv, Anca Dana Buzoianu, Hermann Einsele, Moshe Mittelman, Gabriel Ghiaur, Robert Hasserjian, **Ciprian Tomuleasa**. Cell Death Disease 2025, **impact factor : 8.1**. submitted for publication.

TARGETING DEGRADATION OF IKZF1 AND IKZF3 THROUGH MODULATION OF THE E3 LIGASE SUBSTRATES IN THE CONTEXT OF CELLULAT THERAPIES FOR MULTIPLE MYELOMA. David Keyes, Anamaria Bancos, Adrian Bogdan Tigiu, Ioana Rus, Delia Dima, Diana Cenariu, Madalina Nistor, Diana Gulei, Alina Tanase, Anca Colita, Anca Buzoianu, Cristina Iuga, Mihnea Zdrengea, Evangelos Terpos, Stefan O. Ciurea, Aaron Ciechanover, Hermann Einsele, **Ciprian Tomuleasa**. Journal of Hematology and Oncology 2025, **impact factor : 29.9**, submitted for publication.

ADOPTIVE CELLULAR THERAPIES IN MULTIPLE MYELOMA. David Keyes, Bogdan Borlea, Marc Damian, Adrian Bogdan Tigiu, Madalina Nistor, Diana Cenariu, Raluca Munteanu, Diana Gulei, Angela Dascalescu, Ion Antohe, Alina Tanase, Evangelos Terpos, Hermann Einsele, **Ciprian Tomuleasa**. Best Practice & Research Clinical Hematology 2025, submitted for publication. **impact factor: 2.2**.

Granturi coordonate

Nr.	Mecanism de finanțare	Proiecte	Poziție	Perioadă	Buget partener (EURO)
1	Grant obținut în urma competiției internaționale de cercetare România – Spațiul Economic European (SEE), 2014–2016	Abordare nanotehnologică în gestionarea leucemiei mieloide acute – Colaborare cu Norvegia (Universitatea din Bergen) – acronim: NanoLAM	Manager de grant pentru instituția parteneră - Institutul Oncologic „Ion Chiricuță” (Investigator principal – Prof. Andrei Cucuianu, UMF „Iuliu Hațieganu” Cluj-Napoca). Co-investigator principal: Prof. Emmet McCormack – Universitatea din Bergen, Norvegia	2014–2016	110.000
2	Competiția internă de granturi pentru tineri cercetători, UMF „Iuliu Hațieganu”, 2014–2015	Mecanisme celulare și moleculare ale mielofibrozei primare	Investigator principal – UMF „Iuliu Hațieganu”	2014–2015	8.000
3	Grant SEE, 2015–2016	Chimioterapie inovatoare bazată pe nanoparticule pentru LMA – colaborare cu Norvegia – acronim: NanoChemotherapy	Investigator principal – UMF „Iuliu Hațieganu”. Co-investigator: Prof. Emmet McCormack	2015–2016	41.000
4	Grant echipe tinere, Ministerul Cercetării, 2016–2017	Secvențiere paralelă de înaltă performanță pentru identificarea microARN-urilor diferențial exprimate în cancere cu punct de origine necunoscut	Investigator principal – UMF „Iuliu Hațieganu”	2016–2017	125.000
5	Grant intern pentru studenți, 2015–2016	Letalitate sintetică în chimioterapia LMA: inhibitori PARP +	Mentor grant – Grigore Gafencu	2015–2016	2.000

Nr.	Mecanism de finanțare	Proiecte	Poziție	Perioadă	Buget partener (EURO)
		antraciclina + decitabina vs antraciclina + decitabina – testare in vitro			
6	Grant intern pentru studenți, 2015–2016	Eficiența pirfenidonei în mielofibroza primară	Mentor grant – Sonia Selicean	2016–2017	2.000
7	Grant bilateral România–China, 2016–2017	Biomarkeri invazivi pentru GVHD post-transplant medular	Investigator principal – UMF „Iuliu Hațieganu”. Co-investigator: Prof. Jianlian Shen – Spitalul General al Marinei, Beijing	2016–2017	9.533
8	Grant FDI, CNFIS, 2017	Instruire modernă pentru profesioniștii din hematologie, oncologie și transplant medular	Investigator principal – UMF „Iuliu Hațieganu”	2017	43.826
9	Grant FDI, CNFIS, 2018	Corelarea curriculumului în medicină moleculară și onco-hematologie cu cererea europeană de forță de muncă	Investigator principal – UMF „Iuliu Hațieganu”	2018	38.922
10	Grant Frontier Research, Ministerul Cercetării, 2017–2022	Nanoparticule magnetoplasmonice multifuncționale pentru aplicații în LMA – acronim: NanoTEX	Manager grant – IO „Ion Chiricuță” (IP: Prof. Emil Burzo, UBB Cluj)	2018–2022	180.000
11	Grant Profesor Invitat 2018 – Gabriel Ghiaur, Johns Hopkins	Investigator principal – UMF „Iuliu Hațieganu”	2018	2.619	
12	Grant bilateral România–China, 2018–2019	Imunoterapie experimentală pentru hemopatii maligne	Investigator principal – UMF „Iuliu Hațieganu”. Co-IP: Prof. Liren Qian, China	2018–2019	8.609
13	Grant FDI, CNFIS, 2019	Creșterea competitivității educației medicale prin alinierea la standardele anglo-saxone	Investigator principal – UMF „Iuliu Hațieganu”	2019	41.916

Nr.	Mecanism de finanțare	Proiecte	Poziție	Perioadă	Buget partener (EURO)
14	Grant SEE, colaborare cu Islanda, 2020–2022	Colaborare strategică în hematologie – acronim: HERO	IP: UMF „Iuliu Hațieganu”. Co-IP: Prof. Olafur Sigurjonsson, Reykjavik	2020–2021	144.153
15	Grant Internațional Novo Nordisk 2020–2022	Consolidarea îngrijirii hemofiliei în nordul României și crearea unui registru național	IP: Societatea Română de Hematologie	2020–2021	81.903
16	Grant postdoc, Ministerul Cercetării, 2020–2022	Evaluarea efectului gonadotropinei corionice umane în transplantul de celule stem	Mentor grant – Dr. Andrei Cismaru	2020–2022	51.667
17	Grant postdoc, Ministerul Cercetării, 2020–2022	Model preclinic pentru evaluarea microARN-505-5p în melanom	Mentor grant – Dr. Diana Gulei	2020–2022	51.667
18	Grant echipe tinere, Ministerul Cercetării, 2020–2022	Protocol Sleeping Beauty pentru dezvoltarea celulelor CAR-T – acronim: SEATTLE	IP: UMF „Iuliu Hațieganu”	2020–2022	93.001
19	Grant bilateral România–Belgia, 2020–2022	SOP-uri în imunoterapie – colaborare Wallonia-România	IP: UMF „Iuliu Hațieganu”. Co-IP: Prof. Jo Caers, Universitatea din Liege	2021–2022	10.561
20	Grant Exploratoriu, Ministerul Cercetării, 2020–2023	Inhibarea NF-kB prin manipularea sistemului ubiquitină-proteazom – acronim: ROME	Co-IP: UMF „Iuliu Hațieganu”. IP: Prof. Aaron Ciechanover (Nobel, 2004)	2021–2024	250.000
21	Grant Exploratoriu, Ministerul Cercetării, 2020–2023	Rolul stromal al CYP26 în homeostazia retinoizilor în SMD – acronim: LONDON	Co-IP: UMF „Iuliu Hațieganu”. IP: Prof. Gabriel Ghiaur	2021–2024	250.000
22	Grant Internațional Novo Nordisk 2022–2024	Îngrijirea hemofiliei în NE României și Moldova; registru în Moldova – România 4	IP: Societatea Română de Hematologie	2022–2024	102.779
23	Grant Ministerul	Secvențierea ca standard	IP: UMF „Iuliu	2022–	222.222

Nr.	Mecanism de finanțare	Proiecte	Poziție	Perioadă	Buget partener (EURO)
	Sănătății, 2022–2023	în diagnosticul hemofiliei și al tulburărilor rare	Hațieganu”. Director grant: Asociația Română de Hemofilie	2023	
24	Grant Academia Română de Științe	Model matematic al hematopoezei clonale	IP: UMF „Iuliu Hațieganu”	2023–2024	10.000
25	Grant Asociația Europeană de Hematologie	CAR NK-cells pentru imunomodularea macrofagilor asociați tumorii	IP: UMF „Iuliu Hațieganu”	2024	20.000
26	Grant PNRR, Guvernul României	Grup de excelență pentru imunoterapii celulare orientate pe microambientul tumoral	Co-IP: UMF „Iuliu Hațieganu”. IP: Prof. Hermann Einsele	2024–2026	996.125
27	Grant bilateral RO-MD	Cercetare în DLBCL HIV(+) – diagnostice și tratamente	IP: UMF „Iuliu Hațieganu”	2024–2025	142.835
28	Grant Premiul Henri Coandă	Evaluarea genomică și metabolomică a rezistenței la venetoclax în LMA	Mentor grant – Dr. David Kegyes	2024	20.000
29	Grant bilateral România–Belgia, 2024–2025	Metilarea ARN ca factor prognostic în SMD tratate cu azacitidină	IP: UMF „Iuliu Hațieganu”. Co-IP: Prof. Ștefan Constantinescu	2024–2025	10.000
30	Grant Comisia Europeană – Rețea Doctorală MSCA	Progres în creșterea supraviețuirii în limfoame și leucemii	Manager grant – UMF „Iuliu Hațieganu”. Co-IP: Prof. Laura Belver, Institutul Josep Carreras, Barcelona	2025–2029	246.245 (din 4.251.582)